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1. INTRODUCTION  
Osteogenesis imperfecta, known also as a “brittle bone disease”, is a group of 
rare genetic disorders of bone fragility. OI estimated is around 1 person per 
25,000–100,000 and is characterized by low bone mass, skeletal deformity, and 
growth deficiency. OI has also numerous extraskeletal features, including blue 
sclera, hearing loss, easy bruising, dentinogenesis imperfecta, joint laxity, and 
pulmonary complications (Martin & Shapiro 2009)(Basel & Steiner 2009) 
(Bregou Bourgeois et al. 2016). Forms of the disease vary widely with clinical 
severity ranging from nearly asymptomatic OI with normal stature, light osteo-
penia and average lifespan to recurrent fractures, skeletal deformations, pro-
found disability, and even death (Rauch & Glorieux 2004). In 1979, four OI 
types (OI type I–IV) based on clinical phenotypes were identified by Sillence 
(Sillence et al. 1979). Current classification system is still in use today, however 
it was updated with three more OI types with unusual histological findings 
(types V–VII). Numbering does not match with severity of the types, but shows 
historical order of their discovery. Type I is the mildest form, which is often 
underdiagnosed due to very light symptoms and non-awareness of health pro-
fessionals. Type II is a prenatally lethal OI form. Among survivors, type III is 
the most severe OI type and stands out with severe deformities and short 
stature. Type IV varies from mild to severe, and represents intermediate form 
between I and III OI types (Sillence et al. 1979) (Clarke et al. 2013). 
In addition to phenotypical diversity, OI is also represented with genetic 
diversity. Until now mutations in more than 17 OI genes are associated with this 
disease. Previous studies have shown that up to 85–90% of the OI patients 
harbor mutations in the type I collagen alpha 1 polypeptide (COL1A1) and 
alpha 2 polypeptide (COL1A2) genes, located at chromosome 17q21.33 and 
7q21.3, respectively. Interestingly, mutations in the COL1A1 and COL1A2 
genes, depending on the location and type of the mutation, can cause a whole 
range of severity, from mild to progressive deformity and mortality forms 
(Marini et al. 2007) (Valadares et al. 2014). The COL1A1 and COL1A2 genes 
code for type I collagen α1 and α2 chains, respectively. Type 1 collagen is one 
of the most abundant protein in the human body. It is a structural component of 
bone, skin, tendons, cornea, and blood vessel walls as well as other connective 
tissues. Only 10–15% of OI mutations occur in non-collagenous genes. 
(Glorieux & Moffatt 2013)(Kocher & Shapiro 1998) (Van Dijk & Sillence 
2014) (Glorieux & Moffatt 2013) (Shapiro 2014). However, despite the fact that 
there has been a significant breakthrough in OI genetics for the past few years, 
absence of mutations in the known OI genes in some patients is still challenging 
for the investigators.  
Both qualitative and quantitative type I collagen defects cause OI (Marini & 
Smith 2015). Major amount of mild OI forms (type I) is induced by a premature 
stop codon in the COL1A1/2 genes, which results in a haplotype insufficiency, 
underlined with a half of the normal collagen amount. However, the collagen 
structural sequence is not altered. Structural or qualitative defects in either of 
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the type I collagen chains are the cause of types II–IV, however, usually appro-
ximately 80% of them are Glycine substitutions with another amino acid 
(Marini & Smith 2015) (Marini et al. 2007). It was hypothesized that due to the 
presence of two 1 and one 2 chains in the procollagen triple helix, COL1A1 
is more susceptible to mutations as it contains more 1 chains in the collagen 
fibrils. COL1A1 gene mutations cause OI more often than COL1A2 gene muta-
tions and tend to be more pathogenic (Marini et al. 2007). 
Although genotype-phenotype correlations are great interest for all OI re-
searchers and clinicians, connections between mutations and OI severity are still 
not clear and require further investigation. Information regarding OI clinical 
features and OI genotypes has not been studied in a Vietnamese population 
before. With high population density, of almost 90 million people, in Vietnam 
we can estimate a valuable number of OI patients. The health system in the 
Vietnam is organized on the basis of three levels, from the national to the com-
munity level. Health services cover emergency care, basic diagnostic proce-
dures and therapies in the hospitals; however, advanced techniques and services 
are limited. Preventive health care and treatment modalities of OI traditionally 
have not been covered by insurance before (Tien et al. 2011). There are many 
hospitals that have OI patients, but focus only on the treatment of patients’ frac-
tures. Focused OI research investment in Vietnam remained still problematic. 
Systematic investigation of rare diseases is important for corretct diagnosis and 
for patient treatment and management. Are there any differences in gene defects 
and clinical features in OI Vietnamese patients in compare with residents of 
other countries? Current study revealed differences in mutation proportions of 
the Vietnamese OI database and the results in other countries. Our findings 
would seem to suggest that there might be some role of the ethnicity factor in 




2. LITERATURE OVERVIEW 
2.1. Normal bone structure  
Bone comprises mineralized extracellular matrix and bone cells. The bone cells 
produce the bone matrix and replace the old matrix with new matrix. The mine-
ralized extracellular matrix is responsible for bone characteristics (Tate 2012).  
 
 
2.1.1. Cellular structure of the bone cells 
Bone cells are represented with osteoblasts, osteocytes, and osteoclasts. Osteo-
blasts are derived from osteogenic cells, which are bone stem cells, and develop 
from the mesenchymal cells, located in the inner layers of the perichondrium, 
periosteum and endosteum. Osteoblasts produce collagen and proteoglycans, 
and release matrix vesicles, which play an important role in stimulation of 
further hydroxyapatite formation and mineralization of the matrix. Osteoblasts 
are also called bone building cells as they provide longitudinal and appositional 
growth of the bone (Tortora & Derrickson 2012) (Tate 2012) (Rizzo 2010) 
(Tortora & Nielsen 2012). 
When the osteoblasts mature, they develop into osteocytes. Osteocytes are 
the main cells of the bone tissue, responsible for daily metabolism function. The 
osteocytes are located in lacunae; the processes of osteocytes are in canaliculi. 
Canaliculi allow osteocytes to maintain contact with each other, and exchange 
nutrients and waste with the blood (Tate 2012) (Rizzo 2010) (Tortora & 
Derrickson 2012). 
Osteoclasts secrete an acid locally to demineralize, and enzymes (cathepsin 
K, collagenase etc.) to digest proteins of the bone extracellular matrix. Hence, 
osteoclasts are known as breakdown bone cells. They are responsible for bone 
resorption during normal osteogenesis process or bone repair. Osteoclasts are 
large cells, located in the endosteum (Tate 2012) (Rizzo 2010). 
Depending on the amount of space and bone matrix, bone tissue can be 
divided into two different kinds: compact (or dense) bone and cancellous (or 
spongy) bone. Dense bone, with more bone matrix and less space, is con-
centrated mainly at the diaphysis of long bones. The little space it has makes it 
strong enough to resist outside forces and protect the bone during movement 
and weight bearing. Spongy bone, with more space and less bone matrix, is 
concentrated in flat bones, and also in epiphyses and metaphyses of long bones. 
The structural unit of cancellous bone is the trabecula. Trabeculae are composed 
of thin rods, connected together and surrounding marrow and blood vessels, 
which fill the holes between the rods. Such a structure increases bone flexi-
bility, reduces the weight of the bone and protects bone marrow (Tate 2012) 
(Rizzo 2010) (Tortora & Derrickson 2012). 
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2.1.2. Bone extracellular matrix and minerals 
The extracellular matrix is composed of 35% organic matter, and 65% inorganic 
component. The organic matter mainly consists of collagen and proteoglycans. 
Collagen fibers form the framework for the deposition of the mineral compo-
nents. The collagen fibers are responsible for flexibility and tensile strength of 
the bone (Tate 2012) (Tortora & Derrickson 2012). 
The inorganic component is a crystallized mineral salt, called hydroxyapati-
te, Ca10(PO4)6(OH)2. It is combination of calcium phosphate salt, Ca3(PO4)2, and 
calcium hydroxide, Ca(OH)2. The inorganic component also includes other 
salts, such as calcium carbonate, (CaCO3), and four main ions: magnesium, 
sulphate, potassium, and fluoride. The crystallized mineral salts are responsible 
for the hardness and compressive strength of the bone (Tortora & Derrickson 
2012) (Martini et al. 2012). 
The combination of collagen and mineral salt properties creates the major 
functional characteristics of the bone (Tate 2012) (Tortora & Derrickson 2012). 
 
 
2.1.3. Collagen type I biosynthesis 
Type I collagen is the most abundant mammalian protein, found throughout the 
body. It is the main component of the bone, skin, tendons, cornea, blood vessel 
walls and other connective tissues, except for cartilaginous tissues (Makareeva & 
Leikin 2014) (Kadler et al. 1996). It is formed from three polypeptide chains as a 
heterotrimer of two identical pro-α1 chains and one pro-α2 chain. The synthesized 
procollagen precursor is translocated into the rough endoplasmic reticulum, where 
post-translation modification and folding take place. Then it is transported to the 
Golgi complex and secreted into the extracellular matrix where C-terminal (PICP) 
and N-terminal (PINP) propeptides are cleaved and collagen type I is formed. 
Fibrils are made by cross-linking of collagen type I molecules. Multiple fibrils are 
concentrated into collagen fibers, which are important contents of the bone 
(Makareeva & Leikin 2014) (Gelse 2003) (Van Dijk & Sillence 2014). The 




Figure 1: Organization of type I collagen fibrils (Garnero 2015) 
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The primary structure of collagen is characterized by the obligatory presence of 
glycines – the smallest amino acid – in every third position. In each α chain a 
repeated Gly-X-Y sequence exists. In each of the three chains, X-Y positions 
are occupied by any amino acid, but about 1/3 of X-positions are frequently 
Proline, and about 1/3 of Y-positions are frequently 4-hydroxyproline (Maka-
reeva & Leikin 2014) (Gelse 2003) (Kadler et al. 1996) (Prockop & Kivirikko 
1995) (Engel & Bächinger 2005).  
The type I collagen triple-helix, with the fold proceeding from the C- to N-
terminal, is unstable and slowly denatures at normal body temperature, which 
creates favourable conditions for the leave of  C- and N- propeptides, as well as 
the combination of other molecules into fibers. These special properties give 
type I collagen its elasticity (Leikina et al. 2002) (Makareeva & Leikin 2014). 
Endoplasmic reticulum (ER) chaperones, binding immunoglobulin protein 
(BiP), glucose-regulated protein94 (GRP94), heat shock protein 47 (HSP47), 
FK506 binding protein (FKBP65), a complex of cartilage associated protein 
(CRTAP), prolyl 3-hydroxylase 1 (P3H1) and peptidyl-prolyl isomerase cyclo-
philin B (CYPB), appear to be required for the triple-helix folding (Makareeva 
& Leikin 2014) (Makareeva et al. 2011). 
 
 
2.2. Collagen and malformation of  
osteogenesis imperfecta bone  
Residues of glycine (Gly) are a component of (Gly-X-Y)n repetitions, where X 
and Y are random amino acids. Substitution of the Gly, positioned in the centre 
of the triple helix, with a different amino acid would prevent interchain hydro-
gen bond formation between the NH-group of Gly and the CO in the X-position 
of a neighbouring chain. Therefore, substitution of Gly residues will cause the 
helix to become bulky and unstructured (Gelse 2003) (Marini et al. 2007). In 
this way, it decreases the helix strength and stability, which are crucially impor-
tant for protein function (Kadler et al. 1996) (Makareeva & Leikin 2014).  
Osteoblasts produce collagen and noncollagenous proteins. Mutations in 
osteoblasts make a defective blueprint, consequently leading to production of 
deformed collagen and malformation of the bone. The osteoblasts contain im-
perfect collagen fibers, while the body demands new bone cells for develop-
ment, so they are continuously involved in the formation of ineffective bone. 
Type I collagen is the major structural protein of bone, so the osteoblasts are 
responsible for the most significant part of skeletal pathophysiology in OI 
(Fedarko 2014)  (Fedarko 2014) (Gajko-Galicka 2002).  
The characteristics of OI bone are poor lamellar pattern, low trabecular 
volume, immature bone structure, as well as dilated endoplasmic reticulum, 
swollen mitochondria, and stromal calcification. Furthermore, the osteoid thick-
ness is decreased, and the number of osteoblasts and osteoclasts are increased. 
OI bone demonstrates changes in mineral composition; presence of calcium, 
phosphorus, and stromal calcification in the bone (Baron et al. 1983) (Cassella 
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et al. 1996) (Fedarko 2014). The number of immature osteoblasts is increased, 
with evidence of a higher Rankl/Opg ratio and tumor necrosis factor (TNF) in 
immature osteoblasts. Osteoclast formation and differentiation stimulation is 
also increased (Li et al. 2010). 
Normally, bone functions are maintained by a balance between the activities 
of osteoblasts and osteoclasts, but if osteoclasts dissolve the bone matrix faster 
than osteoblasts produce new matrix, bone becomes weaker. There is no 
difference between OI and normal bone in osteoclast quality nor quantity, but 
only in osteoblast deficiency. The defective collagen frame leads to an ab-
normal deposition of minerals and higher erosion of bone tissues by osteoclasts 
(Martini et al.2012) (Cassella et al. 1996). 
The reduction of type I collagen in the matrix may cause diminution of the 
skeleton. The three main features on xray are osteoporosis, deformities and 
reduction in size (Cassella et al. 1996). The matrix components in affected bone 
include reduced collagen, osteonectin, biglycan and decorin, but increased 
thrombospondin, fibronectin, and hyaluronan. These changes play an important 
role in OI bone pathology (Gajko-Galicka 2002). Collagen fibers make a frame-
work for deposition of mineral crystals, stick them together, and also attach to 
other molecules. This is essential for normal bone matrix structures and 
characters. Mutations lead to an abnormal quantity or quality of type I collagen, 
and consequently, defective collagen function, abnormal matrix bone, skeletal 
pathophysiology, and expression of the OI clinical phenotype. Inorganic minerals 
account for two thirds the weight of bone. The remaining one third is collagen 
fibers and other non-collagenous proteins. These inorganic components can with-
stand compression but are relatively inflexible. On the other hand, the collagen 
fibers contribute tensile strength to bone, and they sustain stretching, twisting and 
bending forces, but can not withstand compression. Bone is very brittle if the 
amount and quality of collagen are not sufficient (Martini et al.2012)(Makareeva 
& Leikin 2014) (Gajko-Galicka 2002) (Cassella et al. 1996). 
 
 
2.3. Osteogenesis imperfecta overview  
Osteogenesis imperfecta, known also as “brittle bone disease”, is a rare genetic 
disorder of bone metabolism. The incidence of OI worldwide varies; it ranges 
from 1/100,000 to 1/25,000, depending on the OI type being considered (Sil-
lence et al. 1979) (Martin & Shapiro 2009) (Basel & Steiner 2009). OI is 
characterized by low bone mass, bone fragility from minimal trauma or normal 
weight bearing, and skeletal deformity. The variability of the condition ranges 
from mild osteopenia to severe deforming and lethal forms, and represents a 
continuum of severity. In addition to bone fragility and skeletal deformities, 
patients may develop secondary clinical features, such as a short stature, 
dentinogenesis imperfecta, joint laxity, blue or greyish eye sclerae, progressive 
hearing loss, and neurological and pulmonary complications. There is no 
evidence of an association between autosomal dominant OI with gender, race, 
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or ethnic group (Sillence et al. 1979) (Glorieux 2008) (Marini & Smith 2015) 
(Maasalu et al. 2015).    
At present, nineteen different genes, connected to OI have been identified 
(“Switch Gene – Osteogenesis Imperfecta Variant Database – Leiden Open 
Variation Database”). About 90% of OI cases arise due to mutations in the 
COL1A1 and COL1A2 genes, which code for collagen type I α1 and α2 chains 
respectively and inherited by autosomal dominent way. The rest of cases are 
represented by mostly recessive mutations in the genes which are connected to 
collagen type I post-translational modifications (cartilage associated protein 
(CRTAP), leucine proline-enriched proteoglycan 1 (LEPRE1), peptidylprolyl 
isomerase B (PPIB), procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 
(PLOD2), beta-subunit of prolyl 4-hydroxylase (P4HB)), folding and transport 
(serpin family H member 1 (SERPINH1), FK506 binding protein 10 (FKBP10), 
SEC24 family member D (SEC24D)), osteoblast proliferation (serine protease 7 
(SP7), cAMP responsive element binding protein 3 like 1 (CREB3L1)), osteo-
clast maintenance (plastin 3 (PLS3)), extracellular matrix formation (bone 
morphogenetic protein 1 (BMP1), secreted protein acidic cysteine (SPARC)) 
and mineralization (serpin family F member 1 (SERPINF1), interferon-induced 
transmembrane protein 5 (IFITM5)), or cell signaling (wingless-type family 
member 1(WNT1), transmembrane protein 38B (TMEM38B)) (Roughley et al. 
2003) (Forlino et al. 2011) (Glorieux & Moffatt 2013) (Valadares et al. 2014) 
(Marini et al. 2014) (Van Dijk & Sillence 2014). Some OI cases remain 
genetically undiagnosed. Underlying this is the fact that OI pathogenesis and 
genetics are not completely known. The presence of other OI molecular defects 
has been hypothesized (Christiansen et al. 2010).  
In 1979, David Sillence with his coworkers classified OI into four types (I–
IV). Type I is mild, type II is the most severe and prenatally lethal, type III is 
the most severe OI type within survival groups, and type IV is an intermediate 
type between I and III. The initial classification, based on clinical and radio-
graphic signs, is still in use today (Sillence et al. 1979) (Clarke et al. 2013). 
 
 
2.3.1. History of osteogenesis imperfecta 
Osteogenesis imperfecta is known under various names: Brittle bone disease; 
fragilitas ossium; Ekman, Lobstein or Vrolik disease (Seedorrf 1949) (Sillence 
et al. 1979) (Sillence & Lamandé 2014). The first time OI was described was in 
an Egyptian mummy dated by paleopathologists to be from around 1000 BC. 
An OI infant skeleton was identified by its thin long bones, dentinogenesis 
imperfecta (DI) and skull deformities such as vertical flattening and transverse 
widening (Lowenstein 2009). In 1674 Melabranche reported a male patient, 
who suffered from multiple bone fractures throughout his life. In the year 1788, 
Olaus Jacobus Ekman described this using the name “osteomalacia” in some 
cases. Edmond (1831) described some of his patients, as people with blue 
sclerae, hypermobility of the joints, bone brittleness and short stature. In 1883 
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Lobstein studied and described the nature of genetic “brittle bone disease”, so 
OI was named after him, as Lobstein’s syndrome. The term “osteogenesis 
imperfecta“ was introduced by Dutch anatomist Willem Vrolik (1801–1863), 
who dissected the corpses of OI patients and described skeletal manifestations 
specific to this condition. Sometimes the disease was mentioned as Vrolik 
disease (Seedorrf 1949) (Sillence et al. 1979) (Sillence & Lamandé 2014) 
(Baljet 2002). From 1949 to 1977, there were many reports of pedigrees with 
autosomal recessive or dominant inheritance (Sillence et al. 1979).  
In 1979, Sillence and colleagues published a special classification, based on 
the severity of OI forms. The Sillence classification is still in use for many diag-
nostic applications in clinical and research practice. He also supposed, that 
genetic heterogeneity is the cause of variable OI forms (Sillence et al. 1979). In 
the 1970s and 1980s, new information about heritable disorders of connective 
tissues became available, and was applied to study bone metabolic disorders, 
biologic collagen and in particular OI. There have been many advances in the 
study of the molecular biology, transcription and translation of collagen pro-
teins, and the OI molecular pathology (Sillence & Lamandé 2014) (Cole 1988) 
(Pinnell et al. 1972). In the 21st century, after the invention of modern genetic 
technologies, knowledge about genetic and molecular heterogeneity of the 
disease expanded significantly. So far, scientists have discovered 17 genes 




OI occurs worldwide and the precise incidence of the disorder is unknown so 
far. Sillence et al. reported in 1979 a minimum incidence of 3.5/100,000 live 
births for OI type I, 1.6/100,000 live births for type II; and 1/68,800 live births 
for type III in Australia (Shapiro 2014) (Sillence et al. 1979). The frequency of 
each OI type, according to types of the Sillence classification, are 45% for type 
I, 10% for type II, 25% and 20% for type III and type IV, respectively (Martin 
& Shapiro 2009). The incidence of OI type II in Northern Ireland was 1.5/ 
100,000 (Donnelly et al. 2010). The incidence in nine South American 
countries, from 1983 to 1987, was 0.4/10,000 births, according to the ECLAMC 
(Latin-American Collaborative Study of Congenital Malformations) database 
(Orioli et al. 1986) (Martin & Shapiro 2009). The estimated population of OI 
sufferers across the rest of the world is 500,000, with an incidence of 0.008% 
and no differences in gender or ethnicity  (Shapiro 2014). The prevalence of the 
disorder is low. OI case reports vary between countries, but the most common 
reported incidence is about 1/15,000 – 1/20,000  births. The measurement of 
incidence has been based on the diagnosis of OI infants (Pollitt et al. 2006) 
(Shapiro 2014).  
In the United States, the OI incidence is estimated as 1/10,000 live births, 
and there are predicted to be approximately 25,000 to 50,000 OI patients 
(Martin & Shapiro 2009). The population prevalence was 10.6/100,000 in Den-
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mark (Andersen & Hauge 1989). About 400 affected people are born each year 
in USA. In the United Kingdom, the estimated number of patients is 3,400 indi-
viduals (coresponding to a prevalence of  6/100,000) (Table 1) (Shapiro 2014). 
 
 
Table 1. Incidence or prevalance of OI in the countries 
Country Incidence or Prevalance*
American 10/100,000 
Denmark 10.6/100,000*
Northern Ireland 1/100,000 
Sweden 7.4/100,000*
South American 4/100,000 




2.4. Osteogenesis imperfecta types 
2.4.1. Sillence classification (Type I–IV) and phenotypes 
David Sillence and his collegues, from the Department of Medical Genetics, 
University of Melbourne, presented an OI classification in 1979, which is still 
in use today. The classification is based on clinical syndromes, X-ray and 
genetic features of OI patients (Sillence et al. 1979) (Van Dijk et al. 2010) 
(Clarke et al. 2013). Sillence explored OI cases from Melbourne and satellite 
hospitals during the period 1955–1977 (Sillence et al. 1979). The Sillence 
classification divides OI into four basic types (Sillence et al. 1979) (Clarke et al. 
2013) (Womack 2014). The type I unites patients with some fractures, variable 
blue sclerae, and hearing loss. The type II is connected to neonatal fractures and 
lethality before or after birth. The type III includes those patients who have 
intrauterine fractures, fractures during delivery or early after birth, severe defor-
mity of rib, limbs and spine, but normal sclerae. The type IV of patients show 
distinct deformity of long bones, but have normal sclerae (Sillence et al. 1979)  
(Clarke et al. 2013) (Rimoin 1978) (Womack 2014). 
 
OI type I. This is the most common OI type, caused by autosomal dominant 
mutations in one of either the COL1A1 or COL1A2 genes, usually due to a 
premature stop codon, which induces quantitative collagen type I defects; the 
collagen is normal but insufficient (Clarke et al. 2013) (Arundel & Bishop 
2010). Due to inheritance patterns, the description of genealogical information, 
and systematization of phenotype manifestations of affected OI family members 
should be carefully assessed (Sillence et al. 1979) (Cole 1988). OI type I is the 
mildest OI form with a birth incidence of 1/25,000 live births (Steiner et 
al.2013) (Van Dijk & Sillence 2014). Sufferers are of normal birthweight and 
length, and rarely have multiple fractures at birth (Rimoin 1978). The number 
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of fractures is usually less than in the case of other types (Glorieux 2008). The 
first fracture in most patients usually occurs sometime in their preschool period. 
Incidence of fractures tends to decrease after puberty and a new wave of 
fractures begins in later adult years in postmenopausal women and elder men, 
connected to osteoporosis susceptibility circumstance (Sillence et al. 1979) 
(Cole 1988) (Glorieux 2008) (Riggs 1991). The fractures heal well because of 
normal modelling of epiphyses, metaphyses and diaphyses of long bones (Cole 
1988). Skeletal deformities are usually mild, with minimal bowing of long 
bones and mild scoliosis due to vertebral fractures  (Arundel & Bishop 2010)  
(Van Dijk & Sillence 2014). 
Type I involves hearing loss of varying degrees, that may be detectable in 
infancy (Womack 2014) (Cole 1988) (Van Dijk & Sillence 2014). The majority 
of patients suffer from progressive hearing loss; 40% of adults have severe 
hearing impairment, and it starts when the patient is around 30 years old and 
tends to get worse (Sillence et al. 1979). Type I can be subdivided into types IA 
and IB depending on the presence or absence respectively of DI (Paterson et 
al.1983) (Arundel & Bishop 2010). Patients with DI have a significantly more 
fractures, as well as fractures at birth, more severe short stature and greater 
skeletal deformity than patients without DI (Van Dijk & Sillence 2014) 
(Paterson et.al.1983).. 
The presence of blue sclerae or pale blueness is due to either thin sclerae or 
normal sclera thickness but with abnormal arrangement of the collagen mole-
cular framework (Sillence et al. 1979) (Blumcke et al. 1972). Type I OI is 
linked with blue sclerae in most cases, and also easy bruising, and joint hyper-
mobility (Sillence et al. 1979) (Van Dijk & Sillence 2014). 
 
OI type II. OI type II is the most severe, lethal form of OI, and occurs in 10% 
of the OI population (Sillence et al. 1979) (Womack 2014) (Glorieux 2008). 
Rarely these babies survive; one-fifth are stillborn and 90% die by 4 weeks of 
age (Van Dijk & Sillence 2014) (Sillence et al. 1984). Type II is caused by 
autosomal dominantly inherited de novo mutations in the collagen genes 
COL1A1 and COL1A2, or autosomal recessively inherited mutation in non-
collagenous genes as CRTAP, LEPRE1, PPIB (Arundel & Bishop 2010) (Van 
Dijk et al. 2010) (Maasalu et al. 2015). Type II can be detected around weeks 
18–20 during the gestation period via routine ultrasounds; images show 
multiple fractures, deformities and bowing of long bones, and extreme under-
ossification of the facial and skull bones (Van Dijk & Sillence 2014) (Sillence 
et al. 1984). 
The estimated incidence of type II is 1–6/100 000 live births (Sillence et al. 
1979). The patients usually die at prenatal age, normally from respiratory failure 
due to rib fractures, short thorax, flail chest, or infection (Sillence et al. 1984).    
The type II phenotype stands out with its extreme skeletal deformities, which 
arise from numerous intrauterine fractures of long bones, ribs and the spine 
(Glorieux 2008) (Arundel & Bishop 2010). The patient has weight and height 
reduction, because of shortening and bowing of long bones. Also, patients 
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develop flattened vertebrae, severe osteoporosis, a small face, accordion-like 
ribs, and dark-blue sclerae bone (Sillence et al. 1979) (Sillence et al. 1984). In 
cases of OI type II, a soft skull is present due to a lack of mineralization, and the 
skeletal system shows reduced cortical bone thickness and amount trabecular 
bone (Sillence et al. 1979) (Glorieux 2008) (Sillence et al. 1984).  
 
OI type III. OI type III is the most severe OI type within survival groups 
(Arundel & Bishop 2010)  (Glorieux 2008). The pattern of inheritance may be 
both autosomal dominant and recessive. Mutations, causing OI type III may 
arise in addition to the collagen genes COL1A1 and COL1A2, also  in recessive  
or so called “non-collagenous OI genes” genes (Arundel & Bishop 2010) (Van 
Dijk et al. 2010). The incidence of this disorder is 1/68,000 live births (Sillence 
et al. 1979). Radiography at birth can detect generalized osteopenia, multiple 
fractures, and bowing long bones (Van Dijk & Sillence 2014). 
Today, the survival time is improved and patients can survive into adult life 
if therapeutic options are followed (Glorieux et al. 1998) (Van Dijk & Sillence 
2014). OI type III sufferers usually die earlier from complications of skeletal 
chest wall deformity, pulmonary hypertension, and/or cardio-respiratory failure 
(Van Dijk & Sillence 2014) (Glorieux et al. 1998). In mild or moderate cases 
the mean life expectancy is similar to original population. 
OI type III is connected to severe bone fragility; an enormous number of 
fractures arise throughout the life of the patient, beginning in utero, and lasting 
into the growing period. Scoliosis and kyphosis cause deformation of the rib cage; 
the wide rib cage overlaps the narrow pelvis (Sillence et al. 1979) (Rimoin 1978) 
(Arundel & Bishop 2010) (Cole 1988) (Glorieux et al. 1998). Skeletal deformity, 
short stature, pale blue or grayish sclerae, barrel-shaped chest with a pectus 
carinatum, and triangular face commonly appear in the patient (Sillence et al. 
1979) (Glorieux 2008) (Cole 1988). The phenotypic traits also may include DI, 
progressive hearing loss, and joint hypermobility (Arundel & Bishop 2010) (Cole 
1988) (Glorieux 2008). Most of the patients are immobile (able only to sit or lay 
down), but some of the patients are able to move with the assistance of walking 
devices (at a younger age) or wheelchair (Lin et al. 2009).   
 
OI type IV. OI type IV is an intermediate type between types I and III. It has a 
diverse phenotype, with moderate severity, which may vary from mild to severe 
forms (Sillence et al. 1979) (Glorieux 2008). It is caused by autosomal domi-
nant mutations in collagen genes COL1A1 and COL1A2, and non-collagenous 
genes by their function as CRTAP, LEPRE1, PPIB (Arundel & Bishop 2010) 
(Van Dijk et al. 2010).  
Patients develop relatively short stature, fractures can happen at birth, and 
their fracture number is variable. Moderate bone deformities are present (Clarke 
et al. 2013) (Glorieux 2008). Non-skeletal traits include normal sclerae, but they 
may be bluish at birth and then fade during childhood (Sillence et al. 1979) 
(Van Dijk & Sillence 2014), and there is the possible presence of DI and 
hearing loss (Sillence et al. 1979) (Cole 1988). 
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2.4.2. New OI classification according to genetic causes 
There is a new OI classification according to genetic causes, comprising 13 OI 
types (Table 2). Every OI type occurs because of a mutated gene. Approxi-
mately 90% of OI cases are caused by a mutation in the COL1A1 and COL1A2 
genes, and are autosomally dominant. These can result in OI types I–IV. The 
other genes, such as IFITM5, CRTAP, LEPRE1, PPIB, SERPINH1, FKBP10,  
SP7, SERPINF1, BMP1, correspond to recessive mutations, and account for 
10% of all OI cases. Type V caused by the IFITM5 gene, is characterized by 
hypertrophic callus and ossification of the interosseous membrane between the 
radius and ulna. Type VI is based on the lack of SERPINF1, leading to minera-
lization deficiencies. Type VII is caused by CRTAP mutations, characterized by 
white sclerae, small heads and short stature. Type VIII is caused by a LEPRE1 
gene mutation, leading to a cruel growth deficiency. Type IX caused by PPIB 
mutation, which affects collagen folding. Types X and XI caused by SERPINH1 
and FKBP10 gene mutations causing the collagen to become disordered in the 
folding procedure. Type XII is based on an SP7 gene mutation, with resultant 
abnormal osteoblast differentiation. Type XIII is caused by a BMP1 gene muta-
tion, with hypermobility of the joints and increased bone mineral concentration 
(Van Dijk et al. 2013) (Van Dijk & Sillence 2014) (Osteogenesis Imperfecta 
Foundation 2015) (Thomas & DiMeglio 2016). 
  
 







COL1A1/2 Structural I–IV I–IV 
IFITM5 Bone mineralization V IV, V 
SERPINF1 Bone mineralization VI III, IV 
CRTAP Collagen type I post-translational modification VII III, IV 
LEPRE1 Collagen type I post-translational modification VIII II, III 
PPIB Collagen type I post-translational modification IX II–IV 
SERPINH1  Collagen chaperon X II, III 
FKBP10 Collagen chaperon XI III, IV 
SP7 Osteoblast transcription factor XII III 





2.4.3. Genes causing OI 
Osteogenesis imperfecta is associated with high genetic heterogeneity. So far, 
mutations in 17 different genes have been found to cause OI phenotypes of 
different severity (Database 2015)  (Van Dijk & Sillence 2014). About 90% of 
the mutations are connected to alterations in the COL1A1 and COL1A2 genes 
(Shaker et al. 2015) (Pollitt et al. 2006). However, with the availability of NGS 
methods, the number of reports about unexpected genetic causes of OI cases has 
significantly increased. Recent findings have proved connections between main-
ly recessive OI forms and non-collagenous genes, which perform collagen post-
translational modifications, transport, matrix mineralization, cell signaling and 
development functions (Marini et al. 2014) (Valadares et al. 2014).  
 
COL1A1 and COL1A2 genes. The COL1A1 and COL1A2 genes are located at 
chromosome positions 17q21.33 and 7q21.3, respectively (MGI 2015). These 
genes code for α1/α2 chains of collagen type I (Arundel 2004)(Van Dijk & 
Sillence 2014). Collagen type I is one the most abundant proteins in the human 
body. It is a structural part of the bone, skin, tendons, cornea, blood vessel walls 
and other connective tissues (Shapiro 2014). At present more than 1500 OI 
mutations have been revealed in collagen genes. The mutations in COL1A1 and 
COL1A2 genes may cause a whole range of OI severity, from mild to pro-
gressive deformity up to lethal (Marini et al. 2007) (Valadares et al. 2014).  
Collagen mutations cause OI, but OI type I is caused by a premature stop 
codon in COL1A1 leading to a normal collagen sequence but half the normal 
collagen amount. On the other hand, types II–IV are caused by structural 
defects in either of the type I collagen chains, usually a glycine substitution 
(about 80%) of another amino acid (Marini et al. 2007) (Marini & Smith 2015). 
 
Non-collagenous osteogenesis imperfecta genes. The IFITM5 gene codes for 
bone restricted interferon induced transmembrane protein-like protein (BRIL) 
and is located at chromosome position 11p15.5. The protein plays a role in bone 
matrix mineralization. The mutations in the 5’ untranslated (UTR) region of the 
IFITM5 gene are associated with moderate, hypertrophic callus and ossification 
of the interosseous membrane (Marini & Smith 2015) (Balasubramanian et al. 
2013). 
The SERPINF1 gene is located at chromosome position 17p13.3 and codes 
for Pigment Epithelium Derived factor protein (PEDF). This protein plays an 
important role in structural development of bone, liver, muscle and fat tissue, 
via inhibition of angiogenesis (Al-Jallad et al. 2014) (Crowe et al. 2009). 
Mutations in the SERPINF1 gene have been identified as the cause of moderate 
to severe OI situations (Crowe et al. 2009) (Valadares et al. 2014). 
The CRTAP gene is located at chromosome position 3p22.3. It codes for 
cartilage-associated protein (CRTAP). Missing or a severely reduced amount of 
the protein causes severe to lethal OI situations (Valadares et al. 2014)  (Morel-
lo et al. 2006). This protein functions as a collagen chaperone and 3-hydro-
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xylates a single proline residue of the α1 chain of collagen type I (I.M. Ben 
Amor et al. 2011)(Morello et al. 2006). The prolyl 3-hydroxylase group is 
encoded by CRTAP, LEPRE1 and PPIB,  responsible for the hydroxylation of a 
single proline residue (P986) in the α1 chain  (Baldridge et al. 2008) (Duran et 
al. 2014) (Willaert et al. 2009). 
The LEPRE1 gene is located at chromosome position 1p34.1, and codes for 
Leucine proline-enriched proteoglycan (leprecan) 1 or Prolyl 3 hydroxylase 1 
(P3H1/LEPRE1). P3H1 is needed for proper collagen synthesis and assembly, 
and is identified as the cause of severe to lethal OI situations (Moul et al. 2013).  
The PPIB gene is located at chromosome position 15q22.31, codes for 
Cyclophilin B (CyPB) (MGI 2015). In the formation of a triple helix, CyPB 
takes the prolyl-containing peptide bonds, identified as having a role in folding, 
stability and secretion of procollagen (Willaert et al. 2009). The mutations in 
PPIB causes a severe to lethal forms of OI (Valadares et al. 2014). 
 The SERPINH1gene, located at chromosome position 11q13.5, codes for 
Heat Shock Protein 47 (HSP47) (Christiansen et al. 2010). The collagen 
chaperone-like protein HSP47 plays an important role in recognizing and 
maintaining the folded state of the type I procollagen trimer (Duran et al. 2014) 
(Macdonald 2001). The mutations in SERPINH1 lead to a severe OI (Valadares 
et al. 2014). 
The FKBP10 gene, located at chromosome position 17q21.2, codes the type 
I procollagen chaperone FKBP65 (Duran et al. 2014) (Barnes et al. 2012) (MGI 
2015). This protein functions as a type I procollagen chaperone, specialized in 
folding (Alanay et al. 2010) (Lapunzina et al. 2010). FKBP10 is identified as 
the gene causing progressive deformity, and contractures (Valadares et al. 2014) 
(Barnes et al. 2012) (Alanay et al. 2010). 
The OSX/SP7 gene, which is located at chromosome position 12q13.13 
(MGI 2015), and encodes an osteoblast-specific transcription factor (SP7/oste-
rix) (Lapunzina et al. 2010) (Shaker et al. 2015). This protein has a special 
function as a transcription factor in osteoblast differentiation and bone forma-
tion (Peng et al. 2013) (Nakashima et al. 2002) (Database 2015). OSX is identi-
fied as a gene causing moderate OI (Valadares et al. 2014). 
The BMP1 gene, located at chromosomeposition 8p21.3 (Database 2015), 
codes for bone morphogenetic protein 1 (BMP1). BMP1 has functions in 
mature collagen type I, the proteolytic processing of the procollagen I C-pro-
peptide (Asharani et al. 2012), and cleavage of the proα(I) C-terminal pro-
peptide (PICP) (Valencia et al. 2014)(Hopkins et al. 2007). The mutation in 
BMP1 is the cause of severe OI.  
The TMEM38B gene, is located at chromosome position 9q31.2 (MGI 2015), 
codes for trimeric intracellular cation channel type B (TRIC-B). TRIC-B con-
ducts calcium flux from intracellular stores and in cell differentiation. Mutations 
in TMEM38B lead to variable OI severity (Rubinato et al. 2014) (Yazawa et al. 
2007). 
The WNT1 gene, located at chromosome position 12q13.12, codes for 
Wingless-type MMTV integration site family member 1 (MGI 2015). WNT1 
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has crucial functions in bone remodeling processing, osteoblast differentiation 
and bone formation, and is required for normal bone homeostasis (Keupp et al. 
2013) (Laine et al. 2013) (Pyott et al. 2013). WNT1 is  identified as the cause of 
early onset osteoporosis and causes variable severity of OI (Laine et al. 2013). 
The SPARC gene, located at chromosome position 5q33.1, codes for secreted 
protein acidic rich cysteine (SPARC). This is a glycoprotein that binds to 
collagen type I and other proteins in the extracellular matrix (Valadares et al. 
2014) (Mendoza-Londono et al. 2015) (Kos & Wilding 2010). The mutation is 
the cause of severe OI (Mendoza-Londono et al. 2015). 
The CREB3L1 gene, which is located at chromosome position 11q11 (MGI 
2015), codes for old astrocyte specifically indused  substance (OASIS) 
(Symoens et al. 2013). OASIS has an important role in the activation of 
COL1A1 transcription, and in facilitating the secretion of matrix proteins 
(Symoens et al. 2013) (Murakami et al. 2009). 
 
 
2.5. Diagnosis of osteogenesis imperfecta  
OI is a rare disease. Underdiagnosis or delay in diagnosis can be common in 
newborns or children. Diagnosis is based on detailed history, as well as clinical 
examination and investigations. However, diagnosis can be difficult in cases 
without history of OI in the family, and in cases with mild symptoms, and also 
when affected adults have no fracture history (Biggin & Munns 2014). De-
pending on the age, we can apply the appropriate diagnostic methods. Intraute-
rine diagnosis can be reliable in cases with family history of OI, investigations 
can be conducted after 16th week of gestation using ultrasound and/or DNA 
analysis. Diagnosis at birth can be made when these are fractures and short 
curved limbs, blue sclerae, also imagines of osteoporosis and wormian bones in 
radiography. A prominent symptom for OI in toddlers is long bone fracturing. 
During childhood and adolescence OI should be suspected when there are 
symptoms of repeated fractures with minor injury and deformity at long bones 
(Cole 1988). With early accurate diagnosis an appropriate care plan can be 
made, which helps to prevent complications, and improve quality of life for OI 
patients and their families. 
 
 
2.5.1. Medical History 
A precise and detailed history is essential for the diagnosis of OI. The important 
thing is to identify the relevant aspects of fractures; their timing, number, 
mechanism, frequency and location. History of dislocation should be explored, 
for shouder, hip, or radial head. When children start to walk, comparison with 
normal children helps in assessing the delay in motor development. Information 
regarding activities and capacity for exercise during school years should be 
obtained, including how long the children can walk, and periods of any immobi-
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lization. OI encompasses a group of heritable disorders, so family history is 
important to know. Attention should be paid to: short stature in adulthood, 
fractures, dislocations, chipped teeth, early onset osteoporosis, and hearing loss. 
As well as any consanguinity, or previous miscarriage should be asked (Sillence 
et al. 1979) (Arundel & Bishop 2010).  
 
 
2.5.2. Clinical signs 
Typical clinical skeletal signs of OI are bone fragility, long bone deformations 
and short stature. There are also several extraskeletal features common to OI. 
These are blue sclerae, DI, and hearing loss.  
The long bone fractures obtained during life is the most important clinical 
symptom. The short bones have smaller load stress so they fracture less than 
long bones (Zeitlin et al. 2003) (Lin et al. 2009). Such fractures are also caused 
by osteoporosis, which develops in most OI cases (Van Dijk & Sillence 2014). 
Long bone fractures can reveal the following potential problems: shortness, 
broadness, crumpling, angulation, and numerous fractures of long bone 
(Sillence et al. 1984). The imperfect subsequent healing following repeated 
fractures and weight-bearing are important causes of deformities in long bone. 
The pronation and supination of the forearm is limited in some cases, due to 
calcification of interosseous membranes, which usually happens between two 
bones – radius and ulna. Calcification of interosseous membranes may cause 
non-traumatic dislocation of the radial head. In the fracture location there may 
present hypertrophic callus (Arundel & Bishop 2010) (Glorieux 2008).  
Bone deformities are common and most frequently observed in long bones. 
Bowing and angulated deformities exist to varying degrees in OI sufferers, with 
frequent over-modeling of the shafts of long bones (Van Dijk & Sillence 2014). 
In addition to long bone deformities occurring due to imperfect bone develop-
ment or fracture healing problems, also weight bearing can cause leg bowing 
(Moriwake & Seino 1997) (Moriwake & Seino 1997). 
Short stature is one of the cardinal features of OI. Endocrine evaluation of 
the growth axis is normal in most patients with collagen defects; however, about 
50% of children had a blunted response to the IGF-1 stimulation test. Given the 
chondroosseus manifestations of recessive OI, it is reasonable to speculate that 
the short stature of dominant OI may be related to abnormalities at the transition 
from cartilage to bone. It is caused by abnormalities in the formation of bone 
from the growth cartilage, while there is no abnormalities in growth hormon 
secretion (Forlino et al. 2011). Mildly-affected persons tend to achieve a normal 
height, but severely-affected patients tend to be of short stature (Biggin & 
Munns 2014). Clinically, there is disproportion between head and body, and 
between upper and lower limbs. Head circumferences are often bigger than in 
non-OI-affected people of the same age. Clinically the short stature shows the 
severity of the disease; shorter is more affected (Sillence et al. 1979).  
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The short stature of OI patients can be also induced by deformities of the 
spine and compression fractures (Wekre et al. 2014). Spine deformity is also 
common. Spinal assessment should be conducted in both a standing and bent 
forward position, with scoliosis or kyphosis present as clinical evidence 
(Arundel & Bishop 2010). Mutation of collagen type I causes hypermobility of 
the spinal ligaments, which in conjunction with the weak bone can create a 
spinal deformity (Lubicky 2012) (Engelbert et al. 2003). On the other hand, 
multiple vertebral fractures also cause deformity. In severe cases, the combi-
nation of multiple rib fractures, semicontinuous beading from fracture calluses 
along each rib, and spinal deformity are responsible for respiratory disorders 
(Van Dijk & Sillence 2014) (Sillence et al. 1984) (Biggin & Munns 2014).  
Skull assessment in OI infants may indicate wide cranial sutures. In severe 
cases, the skull vault can be extremely soft with multiple Wormian bones in the 
posterior skull, and the head may not be in proportion with the short body 
stature. About 30% of OI patients appear to have a triangular face shape. This is 
caused by temporal bossing and a large head (Arundel & Bishop 2010) 
(Sillence et al. 1979).  
Blue sclerae are common in patients under 6 months They tend to last long 
in types I and III OI, and tend to fade in type IV with age (Arundel & Bishop 
2010) (Sillence et al. 1979). The abnormal structure of the sclerae is caused by 
thinner collagen fibers, with diameters 30% less than normal fibers. The 
collagen fibers in OI have no typical cross striations, and are more densely 
packed.The increased transparency in the sclera and diffraction through abnor-
mal sclera causes a blue hue in affected persons (Sillence et al. 1979) (Blumcke 
et al. 1972). 
Dentinogenesis imperfecta (DI) is commonly revealed in association with 
OI. DI is caused by the Dentin Sialophosphoprotein gene (DSPP), which codes 
for main non-collagenous proteins, and for a growth of hydroxyapatite crystal 
(Molla et al. 2014) (Surendra 2013). Dentinogenesis imperfecta is a genetic oral 
disease and it was probably first recognized by Barret in 1882. The term, 
‘dentinogenesis imperfecta’ was coined by Robert and Schour in 1939, as a 
disorder of tooth development problem. This disorder involves discolouration of 
shell-like teeth; they may be yellow, brown or opalescent gray, and translucent. 
The enamel is characterized by hypoplastic or hypocalcified defects in one third 
of cases. The dentin matrix is altered by interglobular calcification (Surendra 
2013) (Sapir & Shapira 2001). Malocclusion, which is classified based on the 
relation between maxillary and mandibular first molars, is also observed in OI 
patients. It is due to a deficiency in the maxilla and not in the mandible growth. 
The maxillary bone is less developed antero-posteriorly, which results in 
midface hypoplasia (Schwartz & Tsipouras 1984). 
Hearing loss is a common clinical symptom in OI. There are many reasons for 
hearing loss in OI patients. It can be caused by abnormal bone formation of the 
cochlea and surrounding structures. The atrophy of cells, vascular structures, and 
bone in the cochlea, or skull fractures can also cause of sensorineural hearing loss. 
Conductive hearing loss is caused by stapes fixation and a mutation in the 
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COL1A1 gene. There is no relationship between the degree of hearing loss and 
mutation type or gene (Swinnen et al. 2009) (Pillion et al. 2011). 
The hypermobility of joints is as common clincal sign in OI. It is caused by 
marked ligamentous laxity, mainly in the metacarpophalangeal and interphalan-
geal joints, hyperflexion of the thumb, and hyperextension of the fingers are 
also common. Hypermobility can be seen in elbows, knees, and in flexion of the 
spine. Incidence between the OI types is not significantly different, but it occurs 
more often in children, than in adults (Sillence et al. 1979) (Brizola et al. 2014). 
As type I collagen is a main component of skin, and plays an important role 
in skin manifestation, and strength of the skin. It is estimated that 70 to 85% of 
the skin is made up of collagen. Therefore a deficiency in the synthesis of type I 
collagen will lead to a change in the mechanical properties of skin. Substitutions 
of amino acids leads to a triple helix that is less stable than normal. The changes 
of quantitative and qualitative type I collagen lead to a reduction in tensile 
strength of the skin. This is explained by the reducible hydroxyproline contents 
of the skin. The thickness of the dermis of affected individuals does not vary 
from normal skin but is typically stiffer and less stretchy than normal skin 




X-ray. Radiographs are not pathognomonic features of OI, but raise suspicion 
for the diagnosis. Plain radiography of the long bones shows the features of 
cortical bone thinning, bone fractures, fracture healing and deformities. Radio-
graphs reveal features of osteopenia and significant reductions (about 30 to 
50%) in calcified bone mass. Radiography of the skull can reveal a prominent 
occipital region, a flattening of the cranial vault, or multiple Wormian bones 
(Semler et al. 2010) (Renaud et al. 2013). On the other hand, depending on OI 
type, radiography can show features of healing fractures, hypertrophic callus, 
ossifications of the interosseous membrane between tibia and fibula, and ulna 
and radius, congenital dislocation of the radial head, popcorn calcifications, 
dense metaphyseal bands and acetabulum protrusion (Renaud et al. 2013) 
(Anticevic et al. 2002). 
 
Dual-energy x-ray absorptiometry. Dual-energy x-ray absorptiometry (DXA) 
is a precise technique used in bone density investigation, and in long-term 
monitoring of patients. It provides quantification of bone mineral content 
(BMC) at specific skeletal sites, and a bone mineral density (BMD) measure-
ment. DXA is used at the lumbar, the cervical spine and the intertrochanteric 
regions of the proximal femur. BMD has no significant differences across OI 
types, but is significant with respect to fracture susceptibility; low BMD para-
meters prognosticate an increased risk of fracture (Anticevic et al. 2002) (Wekre 
et al. 2011) (Melton III et al. 1993). 
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Quantitative computed tomography and Magnetic resonance imaging (MRI) 
have no regular use in OI diagnosis, but sometimes it can be useful in diffe-
rential diagnosis (Arundel & Bishop 2010).  
 
Ultrasound. In cases of antenatal diagnosis, ultrasound has a regular role in the 
diagnosis of OI and it usually done during the second trimester of pregnancy. 
The features found this way are abnormalities of the skull, the rib cage, the 
spine and the limbs. The decreased echogenicity is caused by insufficient mine-
ralization. The deformities are related to fractures, callus formation, increased 
bone plasticity, and micromelia, especially of the femur (King & Bobechko 
1971) (Bulas et al. 1994). Although leg length is normal, bowing of the long 
bones, such as the tibia and femur, can be identified on fetal ultrasound at 22 
weeks gestation to diagnose OI type I in the prenatal setting (Chen et al. 2012). 
Ultrasound is an important tool for both diagnostic and monitoring purposes in 
OI patients, as it easily identifies disturbed bone mass and sructure in these 
patients (Cepollaro et al. 1999).  
 
Bone markers. Bone biochemical parameters are unspecific for investigation of 
OI, but are widely use to monitor on the effect of treatment. Serum levels of 25-
hydroxyvitamin D, PTH, and ionized calcium are found to be normal. In OI 
osteocalcin and alkaline phosphatase are a proteins produced by osteoblasts. 
The results have higher levels of osteocalcin and alkaline phosphatase in serum 
in OI sufferers, even though not significantly different from those in a normal 
group (Cepollaro et al. 1999) (Shapiro & Brennen 2014). The other bone 
markers do not provide evidence for OI diagnosis (Arundel & Bishop 2010) 
(Wekre et al. 2011). Clinically, the concentration of the C-terminal telopeptide 
of type I collagen (PICP) and N-terminal (PINP) propeptides can reflect the 
synthesis of type I collagen, or osteoblast and osteoclastactivity. During pro-
collagen is secreted outside the cell and PINP and PCIP are cleaved; these 
cleavages are assessed by measuring PCIP in-plasma concentration and PINP 
in-urine concentration. If PINP concentration is lower than normal, it suggests 
type I collagen synthesis is occurring at a lower rate, that PICP concentration is 
low, and also decreasing osteoblast action. PICP is significantly reduced in OI 
patients (Cepollaro et al. 1999) (Shapiro & Brennen 2014).  
 
 
2.5.4. Genetic diagnosis of OI  
Genetic testing is the best option to confirm diagnosis for OI. It shows the 
severity of the disease and gives the reccurrent risks for other family members 
and helps in prenatal testing. As a rare Mendelian disorder with extreme genetic 
heterogenity, identification of OI mutations in patients may present some 
difficulties. In the past, OI was proposed as a defect of collagen type I genes. 
However, recent discoveries of new OI-associated genes shifted this paradigm. 
So far, 17 OI-related genes, including COL1A1 and COL1A2, with hetero-
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zygous mutations, which are involved in about 90% of OI cases, have been 
detected (Van Dijk et al. 2013) (Dalgleish 2017). More new OI mutations and 
genes keep being reported.  
There are guidelines for laboratory diagnosis of OI. In 2012, Van Dijk, 
Dangliesh et al. published a workflow for OI molecular genetic diagnosis based 
on modern OI genetic discoveries (Van Dijk et al. 2012). The suggested 
strategy for genetic testing in OI is following: firstly, all exons of collagen type 
I genes COL1A1 and COL1A2 are sequenced. Primers should be designed far 
away from intron–-exon splice sites in order to allow identification of patho-
genic variants in these regions. Then duplication and deletion of the exons, or 
the whole allele, is tested with Multiplex Ligation-Dependent Probe Ampli-
fication (MLPA) or Quantitative Real Time Polymerase Chain Reaction (qPCR) 
analysis. In cases involving the absence of genetic causes of OI in the collagen 
type I gene, analysis should be followed by the sequencing of recessive OI-
related genes (Van Dijk et al. 2012). 
There are many methods for OI mutation discovery. Techniques differ with 
power, accuracy, cost effectiveness and time consumption, revealing unique 
advantages and limitations. The following methods can be usued: qPCR, High 
Resolution Melting, MLPA, linkage analysis, homozygosity analysis, Sanger 
and Next Generation Squencing. From these last two methods are mostly use in 
OI genetic testing.  
 
Sanger sequencing In 1977 Sanger presented a method for DNA sequencing by 
termination with dideoxynucleotides (ddNTPs). The current method is based on 
usual DNA synthesis by the polymerase enzyme; however, in the reaction, in 
addition to deoxynuleotides (dNTPS), ddNTPs are added, which lack the 3’OH 
end and block formation of the phosphodiester bond, and thus stop the synthesis 
of the DNA strand (Sanger F 1977). The ddNTPs are labelled fluorescently with 
dyes of different wavelengths. Capillary electrophoresis separates strands 
according to their length. The fluorescence signal is detected and allows diffe-
rentiation of base pairs (Darst et al. 2010) (Smith et al. 1986). The due-termi-
nator read represents a fluorescent peak chromatogram. The Sanger method 
allows sequencing up to 398 bp. The accuracy of this approach in close to 
99.9% (Anasagasti et al. 2012). 
 
Next Generation Sequencing. Next Generation Sequencing (NGS), was 
designed as a rapid method, to enable sequencing of the whole exome. Since 
NGS became available, more than 100 genes of different Mendelian disorders 
have been discovered (Rabbani et al. 2012). Exons make up only 1% of the 
whole genome (Kumar et al. 2009). Like other monogenic diseases, OI mostly 
alters coding regions, thus exome sequencing is the most appropriate technique 
for detection of new disease-related genes and mutations. Exome sequencing 
kits cover not only exons, but also flanking intron and untranslated (UTR) 
regions, promoters, miRNA genes and non-coding RNAs, which have been 
proved to influence diseases (Bamshad et al. 2011). A lot of recent OI genes 
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and mutations have been discovered with exome sequencing (Becker et al. 
2011) (Cho et al. 2012) (Pyott et al. 2013) (Maasalu et al. 2015).  
Based on availability of patient data, exome sequencing strategies include 
sequencing and filtering of unrelated affected individuals, affected individuals 
from a single family, parents-child trio analysis, or an extreme phenotype 
approach. Filtering minor allele frequency for rare disorders, including OI, 
minor allele frequency must be less than 1%. Variant pathogenicity and conser-
vation should be also taken into consideration (Ku et al. 2011) (Bamshad et al. 
2011). 
SOLiD® exome sequencing is an approach which allows sequencing of 
target genome regions, based on an in-solution hybridization method (Anasa-
gasti et al. 2012). The method combines both high accuracy and throughput. 
Firstly, the DNA is restricted with various enzymes in order to create a shotgun 
library. Next, adaptors are flanked to randomly cleaved DNA. To eliminate off-
target material, probes are hybridized with biotinylated nucleic acids. Strepta-
vidin coated magnetic beads connect with biotin and are then washed (Bamshad 
et al. 2011). At the end of the process, massive parallel sequencing takes place. 
Probes allow sequencing of a multiple number of samples at the same time with 
bar-coding (Ku et al. 2011). 
 
 
2.6. Experience of OI research and  
medical system description in Vietnam 
2.6.1. Health care system description in Vietnam  
Vietnam’s total length from north to south is 1,650 km, lying on the eastern part 
of the Indochinese peninsula. Vietnam is a strip of land shaped like the letter 
“S”. The mainland territory is 331,212 km2, comprising 63 cities and provinces, 
which are divided into 3 regions: North, Central and South. According to World 
Population Prospects, the Vietnam population has reached over 90 million 
people. The birth rate has reached 16.56 births/1,000 population, and the sex 
ratio at birth is currently 1/ 1.12 male/female (United Nations Department of 
Economic and Social Affairs 2014) (GOV.UK 2015). 
The health system is organized on the basis of three levels, from the national 
to the commune level. Firstly, regarding the national level, the Ministry of 
Health (MoH) is responsible for executive decisions and management of the 
entire system. Secondly, there are 63 provincial health bureaus in the country. 
Each bureau implements MoH policies and manages directly their local medical 
network. Finally, the primary level of health network includes district health 
centres, commune health stations and village health workers. There are 10,866 
commune health stations covering nearly all communes in the country (Tien et 
al. 2011) (Oanh et al. 2014) (WHO Asia Pacific Observatory on Health Systems 
and Policies 2015).  
30 
 
The public system still plays a key role in the health care system, including 
hospital, primary health care, prevention medicine and population monitoring 
and family planning. With a mixed public–private hospital system, private 
hospitals account for 8% of hospitals nationwide (StoxPlus 2012). Health insu-
rance was held by 67% of the population in 2012, and the plan is to make that 
100% by 2020. There are full government subsidies (100%) for those who are 
very poor, disabled, widiws, veterans and children under six years of age (Tien 
et al. 2011) (WHO Asia Pacific Observatory on Health Systems and Policies 
2015). Health services cover emergency care, diagnosis and basic therapy in 
hospitals, and high-tech medical services are limited. Fracture and low bone 
mass prevention therapy for OI patient are not been covered by insurance (Tien 
et al. 2011). 
 
 
2.6.2. Osteogenesis imperfecta Vietnamese overview  
With the incidence of OI estimated to be 1/100,000 to 1/25,000 (Basel & 
Steiner 2009) (Martin & Shapiro 2009), we could extrapolate the number of OI 
patients in Vietnam, based on its population of 90 million. Information 
regarding OI clinical features and gene mutations is lacking in Vietnam. Due to 
economic barriers, the laboratory system for OI diagnosis has not been 
developed in Vietnam yet. In keeping with the culture of the Orient, OI patients 
live with their family, and do not get adequate medical care, sustainment or co-
uncelling from the medical community. Vietnam does not yet have an OI 
patient database. However, we have some initial data from Hanoi and Ho Chi 
Minh city – the biggest cities in Vietnam – about clinical experience and treat-
ment of OI with bisphosphonates. Patients in Vietnam are often initially 
diagnosed upon presentation to the hospital after sustaining a fracture. 
The clinical diagnosis and management of patients with OI in Vietnam are 
limited due to lack of diagnostic and therapeutic tools, and due to lack of 
specialists for early prenatal/neonatal screening. Importantly, Vietnam does not 
have a comprehensive programme for OI screening (DNA, RNA blood test for 
family members) or early detection (chorionic villus sampling). It is necessary 
to develop an OI research project in Vietnam, create a primary patient database, 
and to begin both prenatal and neonatal screening for earlier patient identifi-
cation. A good care plan will require the involvement of the patient, family, 
medical and nursing staff, and the community. Systematic investigations into OI 
started in Vietnam in 2013. The main aim of this research is to create an OI 
database in Vietnam, describe genealogical information, systematize phenotype 
manifestations of affected OI family members, and identify mutations of OI 
using Sanger sequencing.  
The results of this study demonstrate that OI has become a challenge in 
Vietnam. Vietnamese OI patients still suffer from a high number of fractures 
and deformations, most likely due to a lack of medical consulting, as well as 
economic difficulties. During this study, the worldwide OI genetic database has 
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been broadened with Vietnamese samples. Comparison of OI mutations in the 
new Vietnamese database with OI database other countries gives us a better 
understanding of OI genotype differences between populations. 
OI early detection and possible prevention should be addressed, particularly 
in pedigree groups with a high risk of OI. A more dynamic investigation and the 
availability of an efficient medical service should be implemented in order to 
improve the quality of life of OI patients and their families in the future. 
 
 
2.6.3. Previous osteogenesis imperfecta research experience   
Previously very little was known about OI in Vietnam.There are some pilot 
research projects about OI at the Center for Gene and Protein at HaNoi Medical 
University, but this is limited to the COL1A1 gene and a few samples (Hanoi 
Medical University 2016). 
There are not so many OI research projects in Vietnam, and most of them 
only focus on the clinical signs (Dung et al. 2013). In these projects the patients 
are diagnosed, monitored and treated in the National Hospital of Pediatric, 
HaNoi City. For OI disease, there is close collaboration between this hospital 
and the OI club. The OI Club of Hanoi is a volunteer organization of families of 
OI patients, enabling their sharing of experiences and mutual support, while 
promoting health education, minimizing OI-related complications and im-
proving quality of life, as well as offering something in the way of rehabilitation 
and treatment. Their research focuses on evaluating the results of treatment with 
bisphosphonates.  
OI is a rare disease and there is no focused research investment in Vietnam. 
There are many hospital in the south of Vietnam that receive OI patients, but 
also to other hospitals focused treatment for patients with fractures. This is 
especially the case with the OI Booming Diamond Center, Ho Chi Minh City, 
where nearly 20 affected individuals regularly board at the center. Here they 
combine traditional medicine with medical treatment and care. They produce a 
traditional medicine, which is an organic material extracted from crocodile 
bone, which is used in the confidence that it will help the body increase the 
production of collagen I. So far, there are many patients following this method. 
The research conducted on this is also limited, and has focused on evaluating 




The estimated incidence of OI is 1/100,000 to 1/25,000 (Basel & Steiner 2009) 
(Martin & Shapiro 2009), but there is little information about OI patients in 
Vietnam, a country with more than 90 million population. Also, basic infor-
mation regarding clinical features and gene mutations of OI is lacking in Viet-
nam. In keeping with the culture of the Orient, OI patients in Vietnam live with 
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their family, and do not get adequate medical care, sustainment or counseling 
from the medical community. There is no systematic recording of OI patient 
clinical information. Patients in Vietnam are often initially diagnosed upon pre-
sentation to the hospital after sustaining a fracture in the community. 
Meeting with OI patients with very different clinical pictures raised some 
questions: how many OI families do we have in total in Vietnam, and are there 
any differences in clinical features or gene defects in Vietnamese OI patients 





3. AIMS OF THE THESIS  
The overall aim of the present thesis was to collect information about patients 
with OI in Vietnam, to investigate their clinical manifestations and genetic 
causes in order to improve the diagnosis and treatment of OI this population. 
 
The specific aims of the thesis were: 
3.1.  To describe the clinical features of patients with OI, and the distribution  of 
different type of OI in Vietnam 
3.2.  To describe the dental occlusal features in patients with OI  
3.3.  To describe the mutations of the COL1A1 and COL1A2 genes in Vietna-







4. METHODS AND MATERIALS  
4.1. Study group 
4.1.1 Data collecting 
We performed a cross-secetional study beginning in September 2013 and con-
cluding in April 2016 aiming to identify families possibly afflicted with OI. We 
requested information about OI patients from all hospitals and medical centers 
in Vietnam and got feedback from these institutions in 34 out of 63 of Viet-
nam’s provinces. Eleven provinces are defined as border zones and due to geo-
graphical reasons are not easily accessible; therefore, they were not included in 
the study.   
Lists of OI patients were collected from hospitals and OI clubs. We then 
connected directly with each OI family to introduce the purpose and ask content 
of the study. One family declined examination and blood testing and was not in-
cluded to the study group. A group of experienced Estonian and Vietnamese 
doctors visited patients' homes and presence of OI clinical features was deter-
mined by them. Two families who did not meet OI clinical criteria were ex-
cluded. 
Finally, in the study group we included 426 individuals from 120 OI 
families, comprising 146 OI patients and their close relatives.  
 
 
4.1.2. Registration of genealogical information  
The data we collected from the families included genealogical and clinical 
information which was all registered in our new database. Interviews with OI 
families were conducted in order to record genealogical information for a mini-
mum of three sequential generations. Genealogical information included OI 
history and family consanguinity data. We gathered information about both 
healthy and affected family members. The history of miscarriages and pregnan-
cies was also reported. A pedigree chart for each family was constructed.  
 
 
4.1.3. Osteogenesis imperfecta phenotype description 
To investigate clinical signs of OI patients, all patients underwent clinical and 
physical examinations. Medical history was confirmed through a review of their 
medical records. Cases were described according to the Sillence classification 
(Types I–IV).  
 Clinical information, medical history, health problems and treatment as-
sociated with OI were recorded from patients medical records or as stated by 
patients. Each patient was examined for skeletal and extraskeletal signs of OI, 
and radiology records, if available, were reviewed. Diagnosis and OI type were 
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confirmed based on observed clinical features and radiological findings. Pheno-
type description was based on:  
a. Patient information and/or medical records, i.e. birth data (height, weight, 
intrauterine and birth fractures), fracture history (time and location of the 
first fracture, total number of fractures and location of fractures). Hearing 
was not tested, but information regarding hearing problems was collected 
from patients and their relatives. 
b. Examination of the patient includes skeletal deformations, non-skeletal OI 
features (hearing loss, presence of DI, sclera colour) and degree of physical 
mobility. Deformities of the skeleton were assessed by observation and 
palpation. Scoliosis, kyphosis and mobility of the spine were assessed in 
different positions, including with the patient bending forward. Weight (kg) 
and height (cm) were measured during examinations.  
c. For occlusal features the data were collected from OI persons in five medical 
centres in Vietnam. One hundred fourteen OI persons participated; among 
them, 62 persons were under 11 years old, 26 were aged from 12 to 16 years, 
and the others were in adult age group. In this study, 12–16 years old 
children (n = 26) were selected because permanent dentition of this age 
group could establish a stable occlusal relationship and eliminate the bias of 
the visible missing teeth variable. Focus was only on analyses of malocclu-
sion of OI persons in this study. The control group consisted of 400 parti-
cipants, including two hundred 12-year-old school children and two hundred 
18-year-old University students. School children were randomly selected 
from five Vietnamese primary schools. Univeristy students were randomly 
selected from Danang University of Medical Technology and Pharmacy, 
Vietnam.  
 
4.2. Genetic studies 
We collected blood samples from 426 individuals – patients, their parents, sib-
lings, and close relatives for genetic analysis. Genomic DNA was extracted from 
EDTA-preserved blood according to standard high-salt extraction methods. It was 
stored at −80°C, and analyzed using Sanger sequencing. 
DNA samples were amplified using a polymerase chain reaction (PCR) with 
25 specially designed primer pairs covering the following: 5’UTR and 3’UTR 
regions and 51 exons of the COL1A1 gene; 36 primer pairs covering the 5’UTR 
and 3’UTR regions and 52 exons of the COL1A2 gene. The PCR reaction was 
performed in a total volume of 20 μl, which included 4 μl of 5x HOT 
FIREPol® Blend Master Mix Ready to Load with 7.5 mM MgCl2 (Solis 
BioDyne, Estonia), 1 μl each of forward and reverse primer (5 pmol), and 1 μl 
of gDNA (50 ng). The PCR reaction was performed with a Thermal Cycler 
(Applied Biosystems, USA) PCR machine. The PCR touchdown program was 





1=95.0°; 15:00 min 
2=95.0°; 0:25 min 
3=64.0°; 0:30 min 
4=72.0°; 0:40 min 
5=Go to 2, 4 times 
6=95.0°; 0:25 min 
7=62.0°; 0:30 min 
8=72.0°; 0:40 min 
9=Go to 6, 30 times 
10=72.0°; 5:00 min 
11=6.0° forever 
 
Amplified PCR products were electrophoresed through a 1.5% agarose gel, to 
control the quality of fragments. The PCR products were then purified with 
Exonuclease I and Shrimp alkaline phosphatase (Thermo Fisher Scientific, 
USA). Sanger sequencing reactions were performed on the purified PCR frag-
ments using a BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Bio-
systems, USA). Reactions were processed using an ABI3730xl instrument.  
Sequence reads were analyzed using Applied Biosystems’ Sequence Scanner 
v1.0 and aligned to the Local Genomic Reference sequence (LGR_1) and GR_2 
of the human reference genome. Raw sequencing data are available from authors 
upon request. Sequence analysis and pathogenic variant identification were 
performed with Mutation Surveyor DNA variant analysis software (Softgenetics, 
USA). Prediction of mutation pathogenicity was performed using Alamut visual 
software (Interactive Biosoftware, France). Mutations were absent from databases 
of normal variations. Variants were checked against the osteogenesis imperfecta 
mutation database ( Dalgliesh 2017). The pathogenicity of the pathogenic variants 
was predicted as a SIFT score (Kumar et al. 2009).  
 
 
4.3. Statistical analysis 
Statistical analysis was performed using the program R (The R Foundation 
2013). The pedigree of each family was constructed using the kinship2 package 
(Sinnwell & Atkinson 2011). The relationship between family members and 
generations was displayed in plots. T-tests were used to determine bivariate 
relationships and a significant difference was considered based on a p value  
< 0.05. For clinical characteristics, general statistics were calculated, including 
mean summary, table, and prop table. Percentage differences were employed to 
evaluate differences in genetic epidemiology of Vietnamese OI patients and the 
distribution of COL1A1 and COL1A2 mutations. 
Dental substudy data were analysed using with Version 17.0 of the Statis-
tical Package for the Social Sciences software (SPSS Inc., Chicago, Illinois, 
USA). Chisquare and Student’s t test determined the significance difference of 
occlusal features between OI and control groups. The confidence level at 95% 




Before the study we applied for study approval from the Ethical Review Com-
mittee on Human Research of Hue University Hospital (approval No. 75/CN-
BVYD) and the Ethical Review Committee on Human Research of the Univer-
sity of Tartu (permit No. 221/M-34). The study was also conducted in accor-
dance with the Helsinki Declaration. The process by which the information and 
samples are collected, coded, stored, tested, and the results explained to parti-
cipating families. Informed written consent from patients or their legal repre-
sentatives was obtained before they were included in the study. Patients who did 
not meet OI clinical criteria or did not want to participate were excluded from 
the study.  
Samples or collected medical information do not carry any personal identi-
fiers. All samples are labeled with subject code that can be traced or linked back 





5.1. Clinical features and phenotype manifestations of  
the patient with osteogenesis imprefecta in Vietnam 
Study group consisted 120 Vietnamese OI families from across the country. The 
families were 30.8%, 44.2% and 25.0% residents of North, Central and South 
Vietnam respectively. The total number of examined OI patients was 146, and 
of them 61 were female and 85 male, the ratio 1:1.39 The largest age group 
(70.55%) of OI patients was 0–15 years. The mean birthweight was 2.7 kg ± 
0.53 for males and 2.6 kg ± 0.43 for females. Birthweight less than 2.5 kg was 
identified in 39 of 146 case which makes 26.7% of the patients. Accroding to 
the Sillence classification, there were 46 patients with OI type I, 46 patients 
with type III and 54 patients with OI type IV (Table 3).  
 
 
Table 3. Characteristics of Vietnamese OI patients 
 
Characteristic Number of patients % 
Gender    
Male 85 58.22 
Female 61 41.78 
Age 
0–5 32 21.92% 
6–10 40 27.40% 
11–15 31 21.23% 
16–20 16 10.96% 
21–25 9 6.16% 
26–30 1 0.68% 
31–35 5 3.42% 
36–40 5 3.42% 
41–45 3 2.05% 
46–50 3 2.05% 
>50 1 0.68% 
Birthweight
Male < 2.5 kg  21 14.38 
Female < 2.5 kg 18 12.33 
No information 7 4.79 
OI Type by Sillence 
I 46 31.51 
II 0 0.00 
III 46 31.51 




The 146 OI patients were born to 133 mothers. Out of these, 36 mothers re-
ported a previous miscarriage. Preterm delivery (less than 37 weeks of gesta-
tion) was detected in 21 mothers. Of the patients, 129 were born to mothers 
under 35 years old (Table 4).  
 
 
Table 4. Characteristics of mothers of Vietnamese OI patients. 
 Number of mothers % 
Miscarriage
Yes 36 27.07% 
No 88 66.17% 
No information 9 6.76% 
Full-term pregnancy 
Yes 111 76.03% 
No (≤ 37 weeks) 21 14.38% 
No information 14 9.59% 
Mother’s age at OI patient’s birth
≤ 35 years old 129 88.36% 
> 35 years old 17 11.64% 
 
 
Genealogical information revealed that 21 families had two or more generations 
of OI. There were 99 families without previous history of OI. Four families 
were found to have twin OI patients, with at least one affected twin. In figure 2 
shown a pedigree where two generations were affected. 
 
 
Figure 2. Pedigree tree of a family with history of OI in two generations 
OI affected family members (circle – female; square – male) are colored. All family 
members marked with solid red (11909, 11917, 11919) and father (11916) were 




Only 12/146 (8.22%) patients were not expressed non-skeletal OI features; 
80.14% patients had blue sclerae, 60.96% patients had DI and 17.81% patients 
suffered from hearing loss. Although skeletal deformities were present in most 
patients (134/146, 91.78%), severity and location of the deformities were 
different. Lower limb deformations were found in 82.88% of the patients and 
upper limb deformations in 54.8% of the patients. Spine deformations were 
present in 62.33% and chest deformations in 50.68% of the patients. Most of the 
patients needed mobility assistance of some level. Only 39.73% patients were 
capable of ambulating independently. The frequency of signs and symptoms 
according to different OI types are presented in Table 5. 
 
 








Number of patients according 







Blue sclera      
Yes 117 80.14% 41 34 42 
No 29 19.86% 5 12 12 
Hearing      
Hearing loss 26 17.81% 5 11 10 
Normal 120 82.19% 41 35 44 
Teeth      
DI 89 60.96% 21 34 34 
Normal 57 39.04% 25 12 20 
Mobility      
Lying 17 11.64% 0 14 3 
Sitting 49 33.56% 0 26 23 
Wheelchair-bound 22 15.07% 3 6 13 
Normal  58 39.73% 43 0 15 
Deformity      
Upper limb 80 54.80% 11 43 26 
Lower limb 121 82.88% 27 45 49 
Spine (scoliosis, kyphosis) 91 62.33% 13 44 34 
Chest 74 50.68% 7 42 25 
 
 
Altogether, 142 of the 146 studied (97.26%) patients had fractures. There were 
four individuals (OI type I) who had not suffered any fractures, but had bone 
deformities, extraskeletal manifestations, and a positive family history typical to 
OI. Of the studied individuals, 125 suffered their first fracture during the first 
six years of life and a total of 34 OI patients had a history of intrauterine 
fractures. Perinatal fractures had occurred in 9 patients. The first fractured bone 
for 92 out of 142 patients (64.79%) was the femur. The femur was also the most 
commonly fractured bone, and was fractured in 132 of the patients (Table 6). 
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The mean number of fractures in the OI type I group was 6.04; in the type III 
group 20.76 and in the type IV group 12.94. Among type III and type IV 
patients, a total of 18 patients each had over 30 fractures during their lifetime. 
 
 
Table 6. Fracture characteristics of 146 Vietnamese OI patients 
 
 Number of patients % 
Time of the first fracture   
Intrauterine 34 23.29% 
Perinatal 9 6.16% 
Before 6 years old 82 56.17% 
≥ 7 years old 14 9.59% 
No information and no fracture* 7 4.79% 
First fractured bone   
Upper arm 15 10.29% 
Forearm 9 6.16% 
Femur 92 63.01% 
Lower leg 14 9.59% 
Mixed (≥ 2 different bones) 9 6.16% 
No information and no fracture* 7 4.79% 
*There were 4 patients without any fractures, and 3 patients could not report the time of 
the first fracture and first fractured bone 
 
 
5.2. Dental features 
Total number of genotyped pateints was 91 and from them 46 patients had DI. 
Out of them 36 were diagnosed with DI. COL1A1 mutations detected on 20 
patients with DI, 16 had COL1A2 mutations and for 10 patients with DI we did 
not detected collagen type I mutation (Figure 3). 
 
 




All genotyped OI cases
91 patients
DI presence  
46 patients
Not DI presence  
45 patients 








Significance of associations between genotype and DI presence was tested with 
Fisher’s test. The results clearly show, that among Vietnamese patients, there is 




Table 7. Comparing of genotypes between patients with and without DI. Statistically 
significant p-value is marked with *. 
 Patients with DI 
N (%) 
Patients without DI 
N (%) 
P-value 
No COL1A1/2 mutations 10 (10.99%) 27 (29.67%)  0.0002661* 
Collagen type I mutations  36 (39.56%) 18 (19.78%) 
COL1A1 mutations 20 (37.04%) 13 (24.07%) 0.3749 
COL1A2 mutations 16 (29.63%) 5 (9.26%)  
 
 
There were significant differences between OI and control groups respectively 
in terms of overjet > 3.5 mm (0.0% and 36.2%, P < 0.001), open bite > 2 mm 
(19.2% and 3.5%, P = 0.004), reverse overjet > 1 mm (76.9% and 8.5%, P < 
0.001), posterior crossbite (34.6% and 6.2%, P < 0.001), and missing teeth 
(42.3% and 2.2%, P < 0.001) (Table 8). 
 
 
Table 8. Occlusal features of OI patients compared to the control group 




Overjet >3.5mm 0.0 36.2 <0.001 
Overbite >3.5mm 26.9 26.0 0.917 
Openbite >2mm 19.2 3.5 0.004 
Contact point displacement >2mm 46.2 54.0 0.437 
Posterior crossbite 34.6 6.2 <0.001 
Reverse overjet >1mm 76.9 8.5 <0.001 
Missing teeth 42.3 2.2 <0.001 
 
 
Most of the occlusal features were found to differ significantly between OI and 
control groups. The OI group had a lower score for anterior maxillary overjet 
(1.44 mm) but a higher score for anterior mandibular overjet (3.94 mm) than the 
control group (3.13 mm and 2.67 mm respectively, P < 0.05). The mean number 
of missing teeth, including anterior teeth and premolars, was also much higher 
in the OI group than in the control group (P < 0.05). The mean score of the 
largest mandibular anterior teeth irregularity for the control group (1.43 mm) 




5.3. Mutational analysis in the COL1A1 and COL1A2 genes  
The sample for this analysis consisted of 91 unrelated osteogenesis imperfecta 
patients. We identified 54 patients (59.4%) with COL1A1 or COL1A2 muta-
tions, 33 (36.3%) with mutations in COL1A1 and 21 (23.1%) in COL1A2. There 
were 34 pathogenic variants in the COL1A1 gene (missense = 23, nonsense = 4, 
splice site = 7) and 22 pathogenic variants in the COL1A2 gene (missense = 21, 
splice site = 1) identified (Figure 4). Of these, 17 novel COL1A1 and 10 novel 
COL1A2 variants have not been reported before, according to the Dalgliesh 
database (Tables 9 & 10). De novo mutations were observed in 50% (17/34) of 
COL1A1 variants and 45.5% (10/22) of COL1A2 variants. Mutations of the 
COL1A1 gene c.2461G>A (p.Gly821Ser) were identified in four unrelated 
patients. Mutation c.2005G>A (p.Ala669Thr) was also identified in two 
unrelated patients. Regarding COL1A1 and COL1A2 mutations, glyceine 
substitutions occurred in 64.3% of cases. 
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Table 9. COL1A1 mutations in unrelated Vietnamese OI patients 
Mutations unreported in the Dalgliesh OI database are marked with an *. In the case of 
heterozygous mutations, both the wild type and mutated alleles are indicated after an 
arrow (>). 
 
No Patient ID COL1A1 mutation  Exon 
Mutation 
type Protein alteration 
1 
 VN01 
c.2461G>GA Exon 37 Missense p.Gly821Ser 
c.2005G>GA* Exon 30 Missense p.Ala669Thr, 
2 VN02 c.1200+1G>GT* Intron 18 Splice site - 
3 VN05 c.1072delC, het* Exon 17 Frameshift p.Glu358Lysfs*26 
4 VN13 c.4391T>C  Exon 52 Missense  p.Leu1464Pro 
5 VN18 c.103+2T>TC* Intron 1 Splice site - 
6 VN21 c.4352dupA, het.* Exon 52 Nonsense Frameshift p.Asp1451Glufs*100 
7 VN26 c.3226G>GA Exon 45 Missense p.Gly1076Ser 
8 VN34 c.2461G>GA  Exon 37 Missense p.Gly821Ser, 
9 VN38 c.959G>GA* Exon 15 Missense p.Gly320Asp 
10 VN39 c.630delG, het* Exon 8 Frameshift p.Glu210Aspfs*3 
11 VN40 c.2461G>GA Exon 37 Missense p.Gly821Ser 
12 VN41 c.1102G>GA Exon 17 Missense p.Gly368Ser 
13 VN49 c.2461G>GA Exon 37 Missense p.Gly821Ser 
14 VN50 c.932G>GT* Exon 14 Missense p.Gly311Val 
15 VN51 c.949G>GA* Exon 14 Missense p.Gly317Ser 
16 VN52 c.2523delT, het.  Exon 37 Frameshift Nonsense p.Gly842Alafs*266 
17 VN58 c.2236-2A>AG* Intron 32 Splice site - 
18 VN66 c.2596G>AG* Exon 38 Missense p.Gly866Ser 
19 VN68 c.2299G>GA Exon 33/34 Missense  p.Gly767Ser 
20 VN70 c.2281G>GA* Exon 33/34 Missense p.Gly761Ser 
21 VN71 c.1002+2T>C Intron 15 Splice site - 
22 VN72 c.1165G>GT  Exon 18 Missense p.Gly389Cys 
23 VN76 c.1165G>GA Exon 18 Missense p.Gly389Ser 
24 VN78 c.3766G>GA  Exon 49 Missense p.Ala1256Thr 
25 VN86 c.977G>AG Exon 15 Missense p.Gly326Asp 
26 VN88 c.2005G>GA* Exon 30 Missense p.Ala669Thr 
27 VN89 c.2005G>GA*  Exon 30 Missense p.Ala669Thr 
28 VN91 c.1299+1G>C Intron 19 Splice site - 
29 VN92 c.2299G>GA Exon 33/34 Missense p.Gly767Ser 
30 VN95 c.590G>GA Exon 8 Missense  p.Gly197Asp 
31 VN99 c.103+2T>TC* Intron 1 Splice site - 
32 VN104 c.3369+1G>GC* Intron 46 Splice site - 




Table 10. COL1A2 mutations in unrelated Vietnamese OI patients 
Mutations unreported in the Dalgliesh OI database are marked with an *. In the case of 











1 VN09 c.3305G>GT Exon 49 Missense p.Gly1102>Val 
2 VN23 c.2261G>GT* Exon 37 Missense p.Gly754Val 
3 VN25 c.1072G>GT Exon 37 Missense p.Gly358Ser 
4 VN29 c.1630G>GA* Exon 28 Missense p.Gly544Ser 
5 VN45 c.1090G>GA Exon 21 Missense p.Gly364Ser 
6 VN47 c.3034G>GA Exon 46 Missense p.Gly1012Ser c.2569C>CA Exon 41 Missense p.Pro857Thr 
7 VN48 c.1451G>GA Exon 25 Missense p.Gly484Glu 
8 VN56 c.1729G>GA* Exon 30 Missense p.Gly577Ser 
9 VN60 c.1009G>GA Exon 19 Missense p.Gly337Ser 
10 VN62 c.1378G>GA Exon 24 Missense p.Gly460Ser 
11 VN64 c.1964G>GT* Exon 32 Missense p.Gly655Val 
12 VN65 c.1981G>GC* Exon 33 Missense p.Gly661Ser 
13 VN69 c.874G>GA Exon 17 Missense p.Gly292Ser 
14 VN81 c.982G>GA Exon 19 Missense p.Gly328Ser 
15 VN82 c.2503G>GA Exon 40 Missense p.Gly835Ser 
16 VN83 c.792+1G>GA Exon 16 Splice site - 
17 VN84 c.2791G>GA* Exon 43 Missense p.Gly931Arg 
18 VN85 c.838G>GT* Exon 17 Missense p.Gly280Cys 
19 VN87 c.2791G>GA* Exon 43 Missense p.Gly931Arg 
20 VN96 c.892G>GT* Exon 18 Missense p.Gly298Cys 





6.1. Clinical features and phenotype manifestations of  
the patient with Osteogenesis Imprefecta in Vietnam 
The data was collected from 34 of Vietnam’s 63 provinces (total population of 
those provinces is 60 million, and of Vietnam 90 million) (Figure 5), spread 
across different geographical areas of Vietnam (Brinkhoff 2014). It is estimated 
that OI affects approximately 1 person per 25,000–100,000 people, however the 
incidence worldwide varies (Basel & Steiner 2009) (Martin & Shapiro 2009). 
Our numbers suggest that OI prevalence is 1/400 000 what is four time less than 
other countries. That may be due to the most probably underdiagnosed in 
Vietnam, especially in cases where there is no history of OI in the family or 









There was a total of 61 female (41.78%) and 85 male (58.22%) OI patients in 
our study, with a 1:1.39 ratio. A study in Taiwan showed a female to male ratio 
of 2.2:1 (Lin et al. 2009). OI is mostly connected to autosomal dominant in-
heritance, which is why there is no difference in gender. Most studies have not 
indicated the gender of affected individuals and OI worldwide usually occurs 
without gender differences (Sillence et al. 1979) (Martin & Shapiro 2009). The 
difference in the gender ratio at birth of OI patients in Vietnam could be 
explained by insufficient diagnosis of OI cases, but could also be related to the 
slightly higher number of male births in Vietnam (the male to female ratio is 
112:100) (Ministry of Planning and Investment 2011).   
We discovered birthweight less than 2.5 kg in 39 OI patients. The mean 
birthweight of healthy Vietnamese boys and girls is 3.1 kg and 3.0 kg, respecti-
vely (Nguyen et al. 2013), the mean birthweight of OI patients in our study was 
2.7 kg for boys and 2.6 kg for girls, respectively, which is significantly lower 
than the healthy population. A prior study describes a mean birth weight of 3.2 
in OI patients (Ben Amor et al. 2013), although does not comment on gestatio-
nal age of these patients. It is unclear from prior studies, as well as this study, if 
and how these birth weights in OI may be related to pregnancy term at delivery. 
Decreased birthweight and short stature of OI sufferers are caused by abnormal 
intrauterine development of the foetus. The difference between the OI groups 
and controls appears to be larger than might be expected from the overall 
smaller body frame in OI (Rauch et al. 2000). In a study by Sillence and collea-
gues, the majority of OI patients also had low birthweight (Sillence et al. 1979). 
In our research, we observed relatively equal number of patients with diffe-
rent OI types; 46 patients with OI types I, 46 with type III and 54 with type IV. 
Other studies have shown that the prevalence of type I patients is usually higher 
compared to types III and IV (Martin & Shapiro 2009). Lin et al. reported OI 
prevalence in Taiwan as follows: 19 OI type I, 10 type III and 19 type IV and 
shows lower prevalence in tuype III (Lin et al. 2009). We were unable to find 
reports of OI type II patients, as this form is typically lethal in the perinatal 
period. The predominance of severe forms of OI in Vietnam suggests under-
diagnosis of mild OI types. 
We have 99 families (82.5%) without a history of OI and only 21 families 
(17.5 %) with OI history in previous generations. Other studies reported a 
positive family history 41–48% (Lin et al. 2009). Seventeen unrelated families 
had 2 or 3 OI children, but their parents did not reveal any OI clinical symptoms 
or OI history. This number may increase after the genetic testing is preformed 
to all family members. Genetic analysis should be done as the next step of our 
research in order to detect OI in subsequent generations in these families.  
Types I and IV have an autosomal dominant inheritance pattern, thus there is 
a 50% chance that parents transmit the OI mutation to their offspring. Recessive 
inheritance patterns of OI mutations usually give rise to OI type III. There is 
also a 1–3% risk of inheriting OI due to gonadal mosaicism in the parents 
(Sharma et al.  2001). 
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Osteogenesis imperfecta in twins is a rare phenomenon. Previously a few 
investigators focused on this topic. According to our best knowledge the only 
work considering osteofenesis imperfecta in twins is done by Gupta and the 
coworkers (Gupta et al. 1990). Interestingly, in our sample, we had four twin 
pairs. Three of the pairs were same sex (2 boys or 2 girls) and one twin pair was 
a boy–girl pair. Two pairs the both of the cildren wre affected and two pairs 
olny one child had clinical signs of OI. The cause may be due to a mutation in 
germ cells. We have found no evidence of OI history in families with twins, nor 
the presence of consanguineous marriage. Further exome sequencing will be 
performed on twin pairs in order to examine the zygosity and genotype–pheno-
type correlations. 
A history of miscarriage was found in mothers of 36 OI patients (27.07%). We 
recorded that 111 mothers (76.03%) had a full-term pregnancy and 21 mothers 
(14.38%) had a premature delivery. The previous study of premature delivery 
including 6.600 pregnant in Vietnam, the proportion is 9.58% (Dat et al. 2013). 
So the premature dilivery occurrence is higher in OI group. The goal of manage-
ment during the perinatal period is to control an atraumatic delivery for both OI 
foetus and mother (Sharma et al. 2001). Most mothers and fathers (129, 88.36% 
and 109, 81.85%) delivered the OI patients when they were under 35 years of age. 
We recognized different levels of severity and localization of deformities in 
patients. Deformities were most frequently observed in long bones. Lower limb 
deformities were found in 121 patients (82.88%), upper limb deformities in 80 
patients (54.80%), spine deformities in 91 patients (62.33%) and chest 
deformities in 74 patients (50.68%). Bowing and angulated deformities exist to 
varying degrees in OI sufferers, with frequent over-modeling of the shafts of long 
bones (Van Dijk & Sillence 2014). In addition to long bone deformities occurring 
due to imperfect bone development or fracture healing problems, weight bearing 
alone can cause leg bowing (Moriwake & Seino 1997). In previous studies, bone 
deformities were reported in 54% of patients (Lin et al. 2009). Lower limb 
deformities were 28.7%, humerus 14.2% (Patel et al. 2015). Scoliosis, kyphosis, 
flattened vertebra and compression fractures are common in OI sufferers. Severe 
vertebral deformity may cause respiratory problems in some patients (Moriwake 
& Seino 1997). Previous studies reported scoliosis in 74.5% (76/102) (Karbowki 
et al. 1999) and 50% (157/316) of cases (Anissipour et al. 2014).  
In our study, 125 patients suffered their first fracture in the first six years of 
life. Sillence also found that fractures usually first appear during the preschool 
period (Sillence et al. 1979). The long bone fractures after minimal trauma were 
the most common and  characterized of OI patient. Fracture rates tend to decrease 
after adolescence (Thomas & DiMeglio 2016). In both genders and for all OI 
types, fracture rates diminish during the teenage years; however the reason is not 
known (Paterson 1997). In our study, 18 patients (12.33%) who had either type III 
or type IV had suffered over 30 fractures. The mean number of lifetime fractures 
for OI patients in our study was 13.23. The mean number of lifetime fractures in 
type I patients was 6.043, in type III patients 20.76 and in type IV patients 12.94. 
There were statistically signficant differences between the number of total 
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fractures between type I and III groups (p = 3.028×10-12), type I and IV groups  
(p = 2.81×10-6) and type III and IV groups (p = 0.0001254). In other previous 
studies, the mean fractures for each OI patient were reported to be 7 (Greeley et 
al. 2013). Most of patients (86%) had sustained fractures, nearly all the 
participants had fractures affecting the long bones (Wekre et al. 2011). Fifty-eight 
unrelated subjects in the study of Zhang and his workers showed 100% patients 
experienced one or more fractures (Zhang et al. 2012) 
Most of the patients in our study required assistance with ambulation: 58 
(39.73%) moved independently; 22 (15.07%) were wheelchair-bound; 49 
(33.56%) were only able to sit; 17 (11.64%) could only be in a lying position. A 
previous study reported that almost 100% of OI type I, 63% of type IV and 0% 
of type III patients were able to walk without aids or supporting devices. 
However 100% of OI type III and 21% of OI type IV patients were reliant on a 
wheelchair (Lin et al. 2009). Wekre reported that 20% (19/97) of patients of all 
OI types, including 100% of OI type III patients, used a wheelchair for 
ambulation (Wekre et al. 2011). OI type III (Figure 6) is connected to severe 
bone fragility, and a significantly increased risk of lifetime fractures, starting as 
early as in the uterus. Scoliosis and kyphosis cause deformations of the rib cage 
(Glorieux 2008). Such OI type III patients develop relatively short stature, and 
fractures can happen at birth with moderate bone deformities present (Glorieux 
2008) (Clarke et al. 2013).  
 
 
A    
 
B   C  
 
Figure 6. Typical patient with OI type III (severe deforming OI)  
X-ray showing: (A) skull, scoliosis and chest deformation; (B) upper limb deformities 
(C) lower limb deformities. 
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The presence of blue sclerae or pale blueness is due to either thin sclerae or 
normal sclera thickness but with abnormal arrangement of the collagen mole-
cular framework (Sillence et al. 1979). We identified 117 patients (80.14%) 
with blue sclerae; out of them 41 had OI type I, 34 had OI type III and 42 had 
OI type IV. The presence of blue sclerae was slightly higher than in previous 
studies, especially for patients with OI type IV. Other OI research studies have 
shown a 75% incidence of blue sclerae; 89%, 80% and 58% for OI types I, III 
and IV respectively (Lin et al. 2009), and a 78.1% (425/544 OI-affected indivi-
duals) incidence of blue sclerae (Patel et al. 2015). 
We found 26 patients (17.81%) with hearing loss of varying levels. Previous 
studies have shown the incidence worldwide to be variable, e.g. 6.7% (Kuurila 
et al. 2000) or 13.4% (73/544) of cases (Patel et al. 2015). There are many pos-
sible reasons for hearing loss in OI patients. It may be caused by the abnormal 
bone formation of the malleus, incus, or stapes of the middle ear (Pillion et al. 
2011); microfractures and incomplete ossification are often found in the otic 
capsule and the malleus in newborns. However, in older patients otospongiosis 
lesions in the footplate of the stapes cause hearing loss. Underminerlization 
imaging of the otic capsule, cochlea, semicircular and auditory canals have been 
revealed on CT scans (Pillion et al. 2011) (Heimert et al. 2002). As we were not 




6.2 Dental features 
In our research DI was identified in 89 patients (60.96%), including 21/46 
(45.65%) OI type I patients, 34/46 (73.91%) OI type III patients and 34/54 
(62.96%) OI type IV patients. The reported prevalence of DI in OI sufferers has 
been highly variable. In a study by Majorana and colleagues, DI prevalence was 
shown to be 62.5% (10/16 OI-affected individuals), with 30% of type III 
patients affected (Majorana et al. 2010). Other authors have reported the 
prevalence of DI to be as low as 19% (Sæves et al. 2009) and as high as 80% 
for OI type III patients (Lin et al. 2009).  
Our results showed strong correlation between presence of the collagen type 
I mutation and DI, and this is in concordance with several previous works 
(Lindahl et al. 2015) (Rauch et al. 2010) (Amor et al. 2011). In the study of 
Taiwanese population no correlation between mutation type and DI was found 
(Lin et al. 2015). 
The main occlusion problems of OI patients were associated with reserve 
overjet. The most obvious difference between OI and control groups in the 
current study concerned reverse overjet. Moreover, open bite was significantly 
higher (> 2 mm) than in the control group. For this reason, we also hypothesize 
that a collagen mutation in the foetal phase might cause structural disorders of 
collagen in the mandibular and condylar regions, leading to the reverse overjet, 
and therefore the gonial angle of the mandible of OI patients is larger compared 
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to those of non-OI individuals. Moreover, spinal curvature and the triangular 
face of OI patients might result in the mandible resting on their chest and open 
bite  (Chang et al. 2007) (Rizkallah et al. 2013) (Minh Son Nguyen et al. 2017).  
The study of Chang et al. 2007 demonstrated the poor growth of the maxilla 
based on analysing cephalometric radiographs of OI patients (Chang et al. 
2007). This finding could explain our results, in that no OI patient had an 
overjet over 3.5 mm, which was however often observed in the control group 
(36.2%), while the crossbite of OI patients (34.6%) was higher than those of the 
control group (6.2%). 
We showed that 42.3% of OI individuals had missing teeth, whereas only 
2.2% of the control group did. The cause of missing teeth could be tooth 
extraction, delayed tooth eruption, hypodontia or abnormal odontogenesis. In 
the current study, missing teeth in the OI group could be referred to genetic 
disorders that would cause hypodontia. Genetic disorders such as cleft lip and 
palate, ectodermal dysplasia or Down’s syndrome are important causes of 
hypodontia (AlShahrani et al. 2013) (Cobourne 2007). The candidate genes, 
therefore, causing missing teeth need to be found in the future. 
 
 
6.3. Mutational analysis in the COL1A1 and COL1A2 genes  
Genetic analysis was performed in 91 unrelated patients. We discovered 
COL1A1 and COL1A2 pathogenic variants in 54 (59.4%) patients. Of these, 33 
patients harboured 34 mutations in the COL1A1 gene, and 21 patients had 22 
mutations and the COL1A2 gene (Figure 4). Previous investigations reported the 
percentage of collagen mutations to be as high as 90% (Pollitt et al. 2006) 
(Shaker et al. 2015), although different mutation rates up to 96% in COL1A1 
and COL1A2 genes occur in different populations (Stephen et al. 2014) (Lee et 
al. 2006) (Zhang et al. 2012). Recently, our research group has finished 
COL1A1/2 mutational analysis in Ukrainian and Estonian OI patients using the 
same methodology of patient recruitment and mutation discovery described in 
the current study of Vietnamese OI patients. The results revealed 89.66% 
(26/29) of individuals harbor collagen type I mutations among Estonian OI 
patients and 65.79% (50/76) among Ukrainian OI patients (unpublished data). 
These findings lend support to the presence of differences in proportions of 
COL1A1/2 mutations between populations, as well as significantly reduced 
number of collagen type I mutations in Vietnamese OI individuals. These 
differences come from the diversity of studied cohort sizes. However, such big 
differences in the Vietnamese population might be also linked to an increased 
number of non-collagenous variants. In order to clarify this phenomenon, the 
cohort of Vietnamese patients must be expanded, and exome analysis in those 
patients who were negative for collagenous mutations must be performed. 
Glycine is situated at every third position in the amino acid sequence of type 
I collagen alfa chains, thus missense OI mutations are usually represented with 
Gly substitutions. We discovered 17/23 and 19/21 Gly substitutions in the 
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COL1A1 and COL1A2 gene missense mutations respectively. The total number 
of Gly substitutions was 36/56 (64.3%) of all collagen mutations.  
In 36 cases Gly was substituted with Serine (Ser) 23 times (63.9%), with 
Valine (Val) 4 times (11.1%), with Cystine (Cys) 3 times (8,3%) and Aspartic 
acid (Asp) 3 times (8,3%). According to earlier investigations, Gly substitution 
with Cys causes the most severe phenotypes, and Gly substitution with Arginine 
(Arg) is often lethal (Cole et al. 1990). The severity of the phenotype depends 
not only on the substituted residue, and differences in properties between amino 
acids, but also on the position of the substitution. Ser was observed as the most 
common amino acid, with which Gly was substituted in Chinese OI patients 
(72%). However, 40% of Taiwanese OI patients harboured mutations, that 
caused Gly substitution with Asp (Zhang et al. 2012) (Lin et al. 2015). The 
reasons for the high diversity in amino acid substitutions between populations 
have not been revealed yet. 
We have discovered 8 intronic variants that cause pathogenic alterations in 
splice sites. In a Chinese study, 7/56 patients were reported to harbour patho-
genic intron variants (Zhang et al. 2012). Splice site mutations are connected to 
exon skipping, intron inclusion, and activation of cryptic sites (Kuivaniemi et 
al. 1997). We have also revealed nonsense variants in exons 52 and 37. Splice 
site and nonsense mutations cause a quantitative defect of collagen type I due to 
haploinsufficiency. Quantitative defects are connected to the mild OI pheno-
type, type I. Sometimes patients develop the moderate phenotype, OI type IV. 
The reasons behind the diversity between carriers of the same mutations are not 
yet known.  
Interestingly, four unrelated patients harboured the same mutation c.2461G>A 
(p.Gly821Ser) in exon 37, in the COL1A1 gene. They may be have a common 
ancestor although nowadays they are living in different parts of the country. 
The COL1A1 heterozygous mutation c.2005G>A (p.Ala669Thr) was shared 
by individuals VN88 and VN89, both with clinical OI type IV. Double 
mutations were described by Zhang et al. and Lee et al. in both the COL1A1 
and COL1A2 genes (Lee et al. 2006). There are more than 1500 mutations 
described in the collagen I genes, supporting the fact, that OI mutations are 
usually individual and it is rare that different unrelated families harbour the 
same pathogenic variants (Lee et al. 2006).  
We also discovered double mutations in two patients; c.2461G>A 
(p.Gly821Ser), and c.2005G>A (p.Ala669Thr) mutations were present in the 
COL1A1 gene of patient VN01, and the second individual, VN47, was a carrier 
of two heterozygous mutations in the COL1A2 gene exon 46 c.3034G>GA 
(p.Gly1012Ser), and exon 41 c.2569C>CA (p.Pro857Thr). Double mutations 
are not rare. Previous investigations have discovered double missense mutations 
in the COL1A2 gene (p.Gly208Glu and p.Gly235Asp), causing the severe OI 
phenotype (types II–III) (Takagi et al. 2015). However, patients from our study 
developed mild and moderate OI with such mutations. Although genotype–
phenotype correlations are of great interest for all OI researchers and clinicians, 
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connections between mutations and OI severity are still not clear and need 
further investigation. 
During our study we discovered 17 and 10 novel mutations in the COL1A1 
and COL1A2 genes respectively (27/56 pathogenic variants; 48.2%). These 
novel mutations were absent from the Dalgleish OI mutation database 
(Dalgleish 2017). Interestingly, in our study there were more new variants com-
pared to studies performed earlier (Stephen et al. 2014) (Lin et al. 2015) (Yang 
et al. 2011) (Ward et al. 2001). Current findings support the presence of an 
unusual mutational profile in the Vietnamese OI population. Future exome 
sequencing is necessary to reveal the rest of the non-collagenous genotypes of 
Vietnamese OI patients. 
OI mutations arose more in the COL1A1 gene than in the COL1A2 gene. In 
the COL1A1 gene, mutation hotspots included the following positions: intron 1, 
exons 8, 14–15, 17–20, 30, 33, 34, 37 and 52. The COL1A2 gene included 
mutation hotspots in exons 17–49. Collagen type I alfa chains consist of a signal 
peptide, an N-terminal propeptide, a chain triple helical domain, and a C-
terminal propeptide. Exons rich with OI mutations correspond to part of the 
protein sequence, which tolerates substitutions of amino acids, resulting in a 
protein with a defective structure, but does not decrease fitness of the fetus, thus 
allowing it to develop. This is in contrast with regions that are crucially 
important for collagen functioning and organism survival that stay free of 
mutations (Marini et al. 2007) (Sweeney et al. 2008). 
Design of sequencing primers allowed the covering of splice site mutations. 
Furthermore, all exons were covered, allowing missense, nonsense and frame-
shift mutations to be revealed in the coding sequence of the COL1A1 and 
COL1A2 genes. Sanger sequencing accuracy is about 99.9%. The only un-
covered changes in the COL1A1 and COL1A2 structures were exon or whole 
gene duplications and deletions (Sanger F 1977). Exon deletions and especially 
whole gene deletions are rare. However, it means that the number of collagen 




1. The results of this study demonstrate that OI has become a challenge in 
Vietnam. The number of affected individuals and severe phenotypes found 
indicates that the disease is most probably underdiagnosed, especially in 
situations with a negative OI family history and in mild cases. Deformities 
and the mean lifetime fracture were higer in our study group. The results of 
this study will be of practical use in educating physicians and other medical 
professionals throughout the Vietnam about the signs and symptoms of OI, 
helping to increase diagnosis and prevent complications of this rare disorder. 
More active investigation and implementation of accessible medical services 
would improve quality of life for OI patients and their families. 
2.  DI was indentifed in 60.96% patients with OI. Genetic analysis suggest 
presence of correlation between DI and abnormality of collagen type I. The 
occlusal features were common in OI patients, especially reverse overjet and 
missing teeth. Due to associated disability and impact on quality of life, 
these conditions often necessitate orthodontic treatment for both medical and 
social purposes. 
3. Mutational analysis of OI patients in Vietnam showed a lower number of OI 
pathogenic variants of collagen in the studied Vietnamese patients compared 
to reported rates for other (including Asian) OI populations. We discovered 
COL1A1 and 2 mutations in 59.4% patients, whereas in most populations the 
rate is around 90%. The outstanding OI mutational profile of the Vietnamese 
population is related to the presence of a high number of recessive mutations 
in non-collagenous OI genes. The reason for unidentified OI genotypes 
remains obscure and needs further investigation, with focus on analysis of 




8. MAIN PRACTICAL APPLICATIONS 
The results of this study demonstrate that OI has become a challenge in Viet-
nam. Vietnamese OI patients face a lack of medical consulting, as well as eco-
nomic difficulties. The creation of an OI database during this study provides a 
better understanding of OI clinical manifestations and also genotype differences 
compared to other populations. 
Better detection of OI disease and earlier prevention should be addressed, 
particularly in families with a high risk of OI. Results from this study will help 
to improve OI detection and investigation, and point out the need for efficient 
medical service in order to improve the quality of life of OI patients and their 
families in the future. For a start, already a medical center for OI patients and 
their families was launched at Hue University Hospital in 2015, and regular 
follow-up and free treatment is now available for all OI patients. Finally, 
however, there is still a need for continuous research to detect differences in 
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10. SUMMARY IN ESTONIAN 
Osteogenesis imperfecta Vietnamis 
Osteogenesis imperfecta on haruldane geneetiline sidekoe haigus, mida nimeta-
takse ka habraste luude haiguseks ning mille esinemissagedus on 1/ 25,000–
100,000 inimese kohta. Osteogenesis imperfecta´le (OI) on iseloomulikud sage-
dased luumurrud, skeleti deformeerumine ja kasvupeetus. Haigusel on ka palju 
skeletiväliseid tunnuseid, nagu sinised skleerad, kuulmislangus ja hammaste 
dentiini häire (dentinogenesis imperfecta). Haiguse kliiniline väljendumine võib 
laialt varieeruda ulatudes kergest vormist kuni letaalseni. Lisaks fenotüübilisele 
mitmekesisusele esineb haigusel ka suur geneetiline heterogeensus. Aastal 1979 
avaldas David Sillence OI klassifikatsiooni, kus eristatakse nelja OI tüüpi (I–
IV) kliinilise fenotüübi alusel. OI haiguse põhjuseks on I tüüpi kollageeni 
sünteesi kvalitatiivne või kvantitatiivne häire. I tüüpi kollageen on väga oluline 
luude, naha, kõõluste, sarvkesta, veresoonte seinte ning samuti teiste sidekudede 
ehitusmaterjal. OI geneetiliseks põhjuseks on peamiselt mutatsioonid kollageeni 
COL1A1 ja COL1A2 geenides ning need võivad põhjustada haigust kergest 
kuni progresseeruvate deformatsioonide perinataalselt letaalse vormini. Seni on 
leitud mutatsioone 17-s erinevas geenis, mis kõik võivad põhjustada erineva 
raskusega haigust. Umbes 90% juhtudest on leitud mutatsioonid COL1A1 ja 
COL1A2 geenides. Kuigi genotüübi ja fenotüübi vahelisi seoseid on palju 
uuritud, siis korrelatsiooni OI kliiniliste tunnuste ja geneetiliste mutatsioonide 
vahel senini leitud ei ole. 
OI on haruldane haigus, mistõttu aladiagnoosimine või diagnoosi hilinemine 
on sagedased. Diagnoosimist aitab lihtsustada perekonna haiguse anamneesi 
teadmine, kliiniliste tunnuste tundmine ja haigete põhjalik uurimine, kuid diag-
noosimine on siiski uutel ja kergete sümptoomidega juhtudel keeruline. Sõltu-
valt arengustaadiumist saab rakendada erinevaid diagnostilisi meetodeid. Prena-
taalne diagnoos on võimalik OI anamneesi korral pärast 16. rasedusnädalat kui 
teostada ultraheliuuring deformatsioonide ja murdude hindamiseks või vaja-
dusel ka DNA analüüs. Sünnihetkel aitavad diagnoosimisele kaasa luumurdude 
ja deformatsioonide esinemine, iseloomulikud muutused röntgen ülesvõtetel 
ning sinise värvusega skleerade esinemine. Lapsepõlve ja noorukieas tuleks hai-
gust kahtlustada kui esinevad sagedased murrud, skeleti deformatsioonid ning 
abiks on ka silmade siniste skleerade või hammaste dentinogeneesi häirete 
esinemine.  
OI esinemist, selle kliinilist väljendumist või geneetilisi põhjuseid Vietnamis 






Käesoleva töö eesmärgid olid: 
1.  Kirjeldada OI patsientidel haiguse kliinilisi tunnuseid ja OI esinemist Viet-
namis 
2.  Kirjeldada hammaste ja hambumusega seotud iseärasusi OI patsientidel 
3.  Kirjeldada COL1A1 ja COL1A2 geenide mutatsioone OI patsientidel Viet-
namis 
 
Materjal ja meetodid 
OI patsientide kaasamine antud uuringusse toimus aastatel 2013–2016. Võima-
likke OI perekondi kaasati üle kogu Vietnami. Päring võimalike OI patsientide 
kohta saadeti kõikidele haiglatele, meditsiinikeskustele ja patsientide organi-
satsioonidele Vietnamis.  
Uuringu andmebaasi registreeriti OI esinemine koos kliiniliste tunnustega 
ning lisaks ka muude oluliste haiguste esinemine perekonnas, koostati sugupuu 
vähemalt kolme järjestikuse põlvkonna isikute andmetega. Kõik patsiendid 
läbisid kliinilise läbivaatuse, mille viis kogu uuringu jooksul läbi sama Eesti-
Vietnami arstide meeskond. Samuti uuriti võimalusel radioloogilisi ülesvõtteid, 
et leida OI tunnuseid ja kirjeldada deformatsioone. Diagnoos ja OI tüüp kin-
nitati kliiniliste tunnuste ja patoloogilise leiu alusel. OI tüüp määrati vastavalt 
Sillence´i klassifikatsioonile. Lisaks fenotüübi kirjeldusele koguti ka täiendavat 
infot nagu sünniandmed (pikkus, kaal, intrauteriinsed ja sündimise käigus esine-
nud luumurrud/deformatsioonid), luumurdude esinemine elu jooksul (murdude 
aeg ja lokalisatsioonid, luumurdude arv kokku), skeleti deformatsioonid, skele-
tivälised OI tunnused (skleerade värvus, dentinogenesis imperfecta (DI), kuul-
mislangus) ja füüsiline aktiivsus ning abivahendite (kargud, ratastool) vajadus.  
Hammaste ja hambumuse täiendavaks uurimiseks valiti 12–16-aastaste OI 
patsientide rühm, kellel esines DI. Andmeid võrreldi kontrollrühmaga, mis 
koosnes 400 isikust. Analüüsisime hammaste kvaliteeti, hinnati nende puudu-
mist ja hambumuse omadusi. 
Kõikidelt patsientidelt ning nende vanematelt koguti vereproovid geneetili-
seks analüüsiks. DNA eraldati EDTA-konserveeritud verest vastavalt standard-
setele eraldamise meetodile. Proove säilitati temperatuuril -80 ° C ja analüüsiti 
kasutades Sanger sekveneerimist. Avastatud patogeenseid variante kirjeldati 




Uuringusse kaasati 120 perekonda, kus esines osteogenesis imperfecta. Kokku 
kanti uuringu andmebaasi 146 OI haiget. Enim OI patsientidest (70.55%) oli 
vanuserühmast 0-15 aastat. Sillence´i klassifikatsiooni järgi esines 46-l pat-
siendil I tüüpi, 46-l III tüüpi ja 54-l patsiendil IV tüüpi OI. Letaalse ehk II tüübi 
OI-ga patsiente ei avastatud. Arvestades Vietnami populatsiooni (ligi 90 mil-
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jonit) on 146 OI haiget väga väike haigestunute hulk. Samuti erineb patsientide 
jagunemine tüüpide vahel oluliselt teistest populatsioonidest, kus on leitud 
ülekaalukalt rohkem I tüüpi (kerge vormiga) haigeid võrreldes raskemate tüüpi-
dega. Me ei eelda, et OI esinemissagedus Vietnamis on ebaproportsionaalselt 
madal või, et raskemate tüüpidega patsiente on Vietnamis ülekaalukalt rohkem. 
Pigem näitavad uuringu tulemused, et OI on Vietnamis oluliselt aladiagnoosi-
tud, eriti juhtudel kui OI ei ole perekonnas varem esinenud või sümptomid on 
kergemad. Väiksemat teadaolevat patsientide hulka võib seostada ka erinevate 
kultuurilisete ja majanduslike teguritega Vietnamis. 
Kuna mõnes perekonnas oli ka mitu OI patsienti, siis erinevaid emasid oli 
kokku 133, kellest 36-l oli esinenud varem raseduste katkemisi ja 21-l enne-
aegne sünnitus. Sugupuude uurimisel selgus, et 21-s perekonnas esines OI ka-
hes või enamas põlvkonnas ning 99-s peres ei olnud varem OI diagnoositud. 
Neljas peres olid kaksikud lapsed, kellest kahel paaril olid OI haiged mõlemad 
kaksikud ja ülejäänud kahest oli haige üks kaksikutest. 
Uuritutest 142-l patsiendil 146-st esinesid luumurrud. Neil OI patsiendil, 
kelle luumurde ei olnud esinenud, leidsime väljendunud luude deformatsioonid, 
lisaks esinesid skeletivälised OI tunnused ning samuti positiivne perekonna 
anamnees. Uuritud patsientidest 34-l oli esinenud luumurd juba intrauteriinselt 
ning 125 olid saanud oma esimese luumurru esimese kuue eluaasta jooksul. 
Sündimise käigus olid luumurrud tekkinud 9-l patsiendil. Esimene murdunud 
luu oli 92-l patsiendil reieluu. Samuti oli reieluu ka üldse kõige sagedamini 
murdunud luu (132 patsiendil). Keskmine luumurdude arv oli I tüüpi OI grupis 
6,04; III tüübi grupis 20,76 ja IV tüübi grupis 12,94. Patsiente, kelle luu-
murdude üldarv ületas 30 oli kokku 18. Skeleti deformatsioone esines enamikel 
patsientidest, kuid erinesid nende lokalisatsioonid ja väljendumine. Ootus-
päraselt esines enim deformatsioone pikkades toruluudes. Alajäseme deformat-
sioone leiti 82,88%-l, ülajäseme deformatsioone 54,8%-l, lülisamba deformat-
sioone 62,33%-l ja rindkere deformatsioone 50,68%-l patsientidest. Enamikul 
uuritud patsientidest esinesid ka skeletiväliseid OI tunnused: 80,14%-l esinesid 
sinise värvusega skleerad; 60,96%-l patsientidest DI ja 17,81%-l kuulmislangus. 
Varasemates uuringutes on näidatud siniste skleerade esinemist 75-78,1%; DI 
esinemiset 19% -62,5% ja kuulmislangust 6,7-13,4% patsientidest. 
Detailsem hammaste ja hambumuse hindamine viidi läbi 26-l OI patsiendil 
vanuses 12-16 aastat, kellel esines DI. Andmeid võrreldi kontrollrühmaga, kuhu 
kuulus 400 isikut. Leiti olulisi erinevusi OI ja kontrollrühma vahel: sagitaalne 
lahi > 3,5 mm (0,0% ja 36,2%, P <0,001), vertikaalne lahihambumus > 2 mm 
(19,2% ja 3,5%, p = 0,004), eesmine risthambumus > 1 mm (76,9% ja 8,5%,  
p <0,001), tagumine risthambumus (34,6% ja 6,2%, p <0,001) ja puuduvad 
hambad (42,3% ja 2,2%, p <0,001). Kõige olulisem erinevus OI ja kontroll-
rühma vahel oli eesmisse risthambumuse osas. Lisaks esines 42,3% uuritavate 
grupist puuduvaid hambaid, samas kui kontrollgrupis puudus hambaid vaid 
2,2%-l. Genotüpiseeriti kokku 91 OI patsienti, kellest 46-l esines DI. Neist 36-l 
leiti I tüüpi kollageeni mutatsioone: 16-l juhul esines COL1A2 mutatsioon ja 
20-l COL1A1 mutatsioon. Seoste tugevuse hindamisel Fisheri testiga selgus, et 
70 
 
Vietnami patsientidel esineb tugev korrelatsioon I tüüpi kollageeni mutatsioo-
nide ja DI esinemise vahel. Sarnaseid tulemusi on leitud ka varasemates uurin-
gutes. 
Kollageeni (COL1A1 ja COL1A2) mutatsioonide analüüs teostati 91 oma-
vahel sugulussidemeid mitteomaval OI patsiendil, kellest 42 oli nais- ja 49 
meessoost. COL1A1 või COL1A2 mutatsioone leiti kokku 54 isikul, neist esi-
nes 33-l COL1A1 ja 21-l COL1A2 mutatsioon. Seega esines kokku 59,4% uuri-
tud isikutest I tüüpi kollageeni mutatsioone, samas kui varasemad uurimised on 
näidanud kollageeni mutatsioone koguni kuni 90%-l patsientidest. Esines 34 
patogeenset COL1A1 geeni varianti ja 22 patogeenset COL1A2 geeni varianti. 
Neist 17 oli COL1A1 ja 10 COL1A2 uudset varianti, mida ei ole varem andme-
baasidesse kantud. De novo mutatsioone täheldati 50%-l COL1A1 mutatsioo-
nidest ja 45,5% COL1A2 mutatsioonidest. Selles uuringus avastatud suur uud-
sete patogeensete variantide hulk erineb varasemate uuringute andmetest.  
Käesolev uuring näitab, et Vietnami osteogenesis imperfecta patsiendid on 
unikaalsed nii fenotüüpide kui genotüüpide poolest ning täiendavate uuringute 




Uuringu tulemused näitavad, et OI avastamine on Vietnamis probleemiks. 
Teadaolevate haigestunud isikute vähesus ja raskete fenotüüpide domineerimine 
näitab, et haigus on tõenäoliselt aladiagnoositud, eriti olukordades, kus OI esi-
nemine perekonnas ei ole teada või haigus esineb kliiniliselt kergel kujul. OI 
patsiendel Vietnamis oli deformatsioonide ning luumurdude keskmine arv kõr-
gem. Antud uurimistöö tulemused on abiks Vietnamis arstidele praktilises töös 
aidates neil paremini ära tunda OI tunnuseid ja parandades diagnoosimise kvali-
teeti. Varasem diagnoosimine ja parem ravi aitavad parandada selle harva-
esineva haigusega isikute elukvaliteeti.  
Dentinogeneesi häire esines 60,96% OI patsientidest. Geneetilise analüüsi 
tulemuste hindamisel leiti tugev korrelatsioon DI ja I tüüpi kollageeni häire 
esinemise vahel. DI patsientidel esines mitmeid hambumuse häireid, millest 
enim olid väljenudnud eesmine risthambumus ning puuduvad hambad. Need 
võivad oluliselt mõjutada patsientide elukvaliteeti ning nõuavad sageli orto-
dontilist ravi meditsiinilisel või sotsiaalsetel põhjustel. 
Mutatsioonide analüüs OI patsientidel näitas oluliselt väiksemat I tüüpi kol-
lageeni mutatsioonide hulka võrreldes teiste populatsioonidega. Antud uuringus 
leidsime COL1A1 ja COL1A 2 mutatsioone 59,4%-l patsientidest, samas kui 
enamikes uuringutes on leitud kollageeni mutatsioone kuni 90%-l OI haigetest. 
Oluliselt erinev OI mutatsioonide profiil Vietnamis on seotud suure hulga 
retsessiivsete mutatsioonidega mitte-kollageeni geenides. Tundmatute OI geno-




11. SUMMARY IN VIETNAMESE 
Bênh tạo xương bất toàn tại Việt Nam 
Bệnh tạo xương bất toàn (TXBT), là bệnh lý tổn thương thành phần collagen 
týp I của mô liên kết. TXBT là bệnh di truyền, hiếm gặp với tỷ lệ xảy ra khoảng 
1/25.000-100.000 người. Tuy nhiên tỷ lệ mắc bệnh rất khác nhau ở mỗi nước 
trên thế giới. Bệnh cảnh lâm sàng không những biểu hiện ở hệ xương như gãy 
xương tự phát, biến dạng xương, lùn, mà còn có biểu hiện ở các cơ quan khác 
như tạo răng bất toàn, giảm thính lực, củng mạc mắt xanh, các khớp lỏng lẻo, 
bất thường kết cấu của da. Năm 1979, Sillence và cộng sự đã dựa vào đặc điểm 
lâm sàng để phân loại bệnh TXBT thành 4 týp. Phân loại này vẫn được sử dụng 
rộng rãi cho đến ngày nay. Collagen týp I là thành phần protein chính được tìm 
thấy trong cấu trúc của xương, da, gân, củng mạc, thành mạch, ngà răng và 
nhiều tổ chức mô liên kết khác. Các gen mã hoá cho sự tổng hợp hoặc cấu trúc 
collagen týp 1 bị đột biến sẽ dẫn đến bệnh TXBT thường gặp là gen COL1A1 
và COL1A2. Khi đột biến làm giảm số lượng collagen có cấu trúc bình thường 
hay bất thường sẽ gây nên các triệu chứng của bệnh từ mức độ nhẹ đến nặng. 
Cho đến nay thế giới đã phát hiện ra 17 loại gen đột biến khác nhau gây nên 
bệnh TXBT. Tuy nhiên các nghiên cứu cho rằng có đến 90% là do đột biến 2 
gen COL1A1 và COL1A2. Ngày nay với sự phát triển của các phương pháp 
“next generation sequencing”, là phương thức giải trình tự đồng thời và lượng 
lớn các đoạn ngắn nucleotide. Nhiều gen gây ra bệnh TXBT đã được phát hiện. 
Gần đây các nhà khoa học đã chứng minh có sự liên kết giữa đột biến gen lặn 
và các gen không phải là collagen.  
Mặc dù sự tương quan giữa kiểu hình và kiểu gen là mối quan tâm đặc biệt 
của các nhà nghiên cứu và lâm sàng, tuy nhiên mối liên quan giữa đột biến gen 
và mức độ trầm trọng của bệnh vẫn chưa được rõ ràng và cần nghiên cứu hơn 
nữa. Bệnh TXBT là bệnh hiếm gặp, vì thế đa số các trường hợp bị bỏ sót trong 
chẩn đoán hoặc chẩn đoán muộn. Chẩn đoán chủ yếu dựa vào tiền sử cá nhân và 
gia đình, khám lâm sàng và xét nghiệm. Những trường hợp khó chẩn đoán 
thường gặp do không có tiền sử bệnh TXBT của gia đình, dấu hiệu lâm sàng 
nhẹ, hoặc cá nhân không có tiền sử gãy xương. Tùy theo từng giai đoạn tuổi mà 
có thể sử dụng các phương pháp chẩn đoán thích hợp. Trong bào thai thì dựa 
vào tiền sử gia đình, siêu âm có thể thực hiện để xác định chẩn đoán vào tuần 
thứ 16 của tuổi thai hoặc phân tích DNA. Chẩn đoán ở giai đoạn sơ sinh thì dựa 
vào xương bị biến dạng cong hoặc gãy, củng mạc mắt xanh, hoặc hình ảnh 
loãng xương của các xương dài hoặc khuyết xương sọ trên X quang. Triệu 
chứng nổi bật để chẩn đoán TXBT ở trẻ em là gãy xương dài, gãy xương lặp lại 
nhiều lần dù chấn thương rất nhỏ, các xương dài bị biến dạng. Cần phải chẩn 
đoán sớm, lập kế hoạch chăm sóc và điều trị thích hợp nhằm ngăn ngừa các 
biến chứng, cải thiện chất lượng cuộc sống của bệnh nhân và gia đình bệnh 
TXBT.  
Với tỷ lệ mắc bệnh chung của thế giới hiện nay, và với dân số Việt Nam hơn 
90 triệu, chúng ta có thể ước tính số lượng bệnh nhân TXBT sẽ rất lớn. Những 
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kiến thức về lâm sàng và đột biến gen của bệnh TXBT chưa được cập nhật ở 
cộng đồng và các cơ sở y tế. Những nghiên cứu về lâm sàng và phân tích gen 
bệnh lý TXBT của người Việt Nam vẫn chưa được công bố rộng rãi trên các 
nghiên cứu quốc tế. Vì vậy, chúng tôi thực hiện đề tài này với mục tiêu: 
 
1. Mô tả các đặc điểm lâm sàng và các thể loại khác nhau của bệnh TXBT tại 
Việt Nam. 
2. Mô tả các đặc điểm về răng và khớp cắn trong bệnh nhân TXBT. 
3. Mô tả đặc điểm đột biến gen COL1A1 và COL1A2 của những người Việt 
Nam bị bệnh TXBT  
 
 
Đối tượng và phương pháp nghiên cứu 
Từ năm 2013 đến 2016, chúng tôi thực hiện một nghiên cứu mô tả cắt ngang về 
bệnh TXBT. Danh sách bệnh nhân được thu thập từ các bệnh viện, trung tâm và 
các câu lạc bộ TXBT trên cả nước. Một nhóm bác sĩ của Bệnh viện Trường Đại 
học Y Dược Huế và Đại học Tartu- Estonia đến thăm khám và thu thập dữ liệu 
tại nhà các gia đình bệnh TXBT. Những gia đình có bệnh TXBT được chọn với 
điều kiện được chẩn đoán đúng TXBT và tình nguyện tham gia vào chương 
trình.  
Những dữ liệu được thu thập bao gồm thông tin về lâm sàng và phả hệ. 
Phỏng vấn trực tiếp các thành viên trong gia đình để thu thập các thông tin xây 
dựng cây phả hệ, bao gồm 3 thế hệ cho mỗi gia đình. Tất cả bệnh nhân được lựa 
chọn đều được thăm khám trực tiếp để ghi nhận tiền sử, bệnh sử, triệu chứng 
lâm sàng, tình trạng chăm sóc, theo dõi, điều trị của bệnh. Thu thập dữ liệu còn 
căn cứ vào các hồ sơ y tế lưu trữ, X quang của mỗi gia đình. Thăm khám ghi 
nhận các triệu chứng của hệ cơ xương khớp, cũng như các cơ quan khác liên 
quan đến bệnh TXBT. Chẩn đoán týp bệnh dựa vào phân độ từ I-IV của 
Sillence. Thông tin về bệnh nhân bao gồm những thông tin lúc mới sinh (cân 
nặng, gãy xương trong bào thai hay khi sinh), tiền sử về gãy xương (thời gian và 
xương gãy lần đầu, ước tính tổng số gãy và xương gãy), biến dạng các xương, 
các triệu chứng ngoài hệ cơ xương khớp như tạo răng bất toàn, giảm thính lực, 
củng mạc mắt xanh. Các mức độ vận động bình thường hay giới hạn vận động 
đi lại. Biến dạng xương cũng được thăm khám và đánh giá. 
Nghiên cứu về các bệnh lý liên quan đến răng và khớp cắn trong TXBT 
được chọn ngẫu nhiên một nhóm bệnh nhân TXBT từ 12 đến 16 tuổi, gồm 26 
bệnh nhân. Nhóm chứng được chọn ngẫu nhiên gồm 200 học sinh phổ thông và 
200 sinh viên đại học. Chúng tôi phân tích các triệu chứng về khớp cắn như độ 
cắn chìa, độ cắn phủ, độ cắn hở, cắn chìa răng dưới, cắn chéo răng sau và mất 
răng. 
Mẫu máu có chống đông EDTA được thu thập từ bệnh nhân, cha mẹ, anh chị 
em, và người thân trong gia đình để phân tích gen. DNA được chiết xuất và 
phân tích giải trình tự theo phương pháp Sanger. Phát hiện các biến thể đột biến 
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dựa vào so sánh trình tự gen của bệnh nhân với trình tự gen chuẩn của ngân 
hàng gen thế giới. 
 
Kết quả 
Chúng tôi thăm khám và chọn lựa 146 bệnh nhân TXBT (61 nữ và 85 nam) từ 
120 gia đình có bệnh TXBT. Các gia đình cư trú ở miền Bắc là 30.8%, miền 
Trung 44.2%, và miền Nam 25.0%. Nhóm bệnh dưới 15 tuổi có số lượng nhiều 
nhất chiếm 70.55%. Theo phân độ của Sillence, týp I có 46 bệnh nhân, týp III 
46 bệnh nhân và týp IV 54 bệnh nhân. Tỷ lệ mắc bệnh TXBT trong nghiên cứu 
của chúng tôi thấp hơn nhiều so với tỷ lệ mắc bệnh hiện hành của thế giới. 
Chúng tôi giả thuyết rằng, tỷ lệ mắc bệnh TXBT thấp có thể do nhiều trường 
hợp chưa được chẩn đoán, đặc biệt những trường hợp bệnh nhẹ hoặc không có 
tiền sử gia đình về bệnh TXBT, đồng thời cũng có thể do đặc điểm về văn hóa 
và tình trạng kinh tế của gia đình. 
146 bệnh nhân TXBT được sinh ra từ 133 bà mẹ, trong đó 36 bà mẹ có tiền 
sử sẩy thai. 21 bệnh nhân bị sinh non (trước 37 tuần thai). Cây phả hệ phát hiện 
21 gia đình có 2 đến 3 thế hệ có bệnh nhân TXBT. 99 gia đình không có tiền sử 
về bệnh trên lâm sàng. Có 4 cặp bệnh nhân sinh đôi. Trong 146 bệnh nhân có 
142 bệnh có tiền sử gãy xương, 4 cá thể chưa gãy xương lần nào nhưng có các 
biểu hiện của TXBT như biến dạng xương, tạo răng bất toàn, giảm thính lực, 
củng mạc mắt xanh, hoặc có tiền sử gia đình bị bệnh TXBT. Có 125 bệnh nhân 
gãy xương lần đầu khi nhỏ hơn 6 tuổi. 34 bệnh nhân được phát hiện gãy xương 
trong bào thai nhờ siêu âm chẩn đoán ở giai đoạn tiền sản, 9 bệnh nhân bị gãy 
xương trong giai đoạn sinh. 132 bệnh nhân có gãy xương đùi trong tiền sử và 92 
bệnh nhân gãy xương đùi là xương gãy đầu tiên. Tỷ lệ trung bình gãy xương ở 
týp I, III, IV lần lượt là 6.04; 20.76 và 12.94. Chúng tôi phát hiện có 18 bệnh 
nhân gãy trên 30 lần trong đời sống của họ. 
Biến dạng cũng gặp ở hầu hết bệnh nhân với những mức độ nặng nhẹ và vị 
trí biến dạng khác nhau. Biến dạng chi dưới chiếm 82.88%, chi trên 54.8%, biến 
dạng cột sống 62.33%, lồng ngực 50.68%. Nghiên cứu của Lin (2009) với 54% 
biến dạng. 
Nghiên cứu của chúng tôi phát hiện 89 bệnh nhân (60.96%) tạo răng bất 
toàn. Theo nghiên cứu của Majorana (2010), tỷ lệ tạo răng bất toàn là 62.5%, 
của Sæves (2009) là 19%. Nghiên cứu cho thấy có 117 bệnh nhân có củng mạc 
mắt xanh (80.14%), báo cáo của tác giả Patel (2015) là 78.1%. Giảm thính lực 
gặp ở 26 bệnh nhân (17.81%). Các nghiên cứu khác của Kuurila (2000) và Patel 
(2005) cho thấy giảm thính lực gặp từ 6.7 đến 13.4%. 
Đánh giá về khớp cắn ở 26 bệnh nhân TXBT (30.8% nữ, và 69.2% nam), so 
sánh với 400 cá thể từ nhóm chứng. Kết quả có sự khác biệt giữa nhóm bệnh và 
chứng về độ cắn chìa > 3.5 mm (0.0% và 36.2%, P < 0.001), độ cắn hở > 2 mm 
(19.2% và 3.5%, P = 0.004), cắn chìa răng dưới > 1 mm (76.9% và 8.5%, P < 
0.001), độ cắn chéo răng sau (34.6% và 6.2%, P < 0.001), mất răng (42.3% và 
2.2%, P < 0.001). Sự khác biệt có ý nghĩa giữa nhóm bệnh và chứng gặp ở cắn 
chìa răng dưới và mất răng. Chúng tôi giả thuyết rằng có sự đột biến của 
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collagen dẫn đến thay đổi cấu trúc các xương hàm trên và hàm dưới, và kết quả 
dẫn đến cắn chìa răng dưới.  
Phân tích đột biến gen COL1A1 và COL1A2 trên 91 bệnh nhân không có 
liên hệ huyết thống, trong đó 46 bệnh nhân có tạo răng bất toàn. Với kết quả 
36/46 bệnh nhân được chẩn đoán đột biến collagen týp I, trong đó 16 bệnh nhân 
đột biến COL1A2 và 20 bệnh nhân đột biến COL1A1. Nghiên cứu đã thể hiện 
sự liên quan giữa đột biến kiểu gen và tạo răng bất toàn, điều này cũng tương tự 
kết quả với các nghiên cứu của tác giả Lindahl (2015), Rauch (2010) và Amor 
(2011). 
Phân tích đột gen trên mẫu máu của 91 bệnh nhân (49 nam và 42 nữ) không 
có liên hệ huyết thống cho kết quả 54 (59.4%) bệnh nhân có đột biến gen 
COL1A1 và COL1A2. Trong đó có 33 (36.3%) bệnh nhân đột biến COL1A1 và 
21 (23.1%) bệnh nhân với COL1A2. Những báo cáo nghiên cứu của Marini 
(2007), Valadares (2014), Van Dijk (2014), Shapiro (2014) cho thấy có đến 
90% đột biến collagen týp I. Mới đây nhóm chúng tôi cũng phân tích đột biến 
collagen týp I trên nhóm bệnh nhân Estonia và Ukraina, cùng một phương pháp 
chọn mẫu và phân tích, cho kết quả đột biến collagen týp I là 89.66% (26/29) ở 
Estonia và 65.79% (50/76) ở Ukraina. Kết quả này củng cố thêm giả thuyết có 
sự khác biệt về tỷ lệ đột biến gen COL1A1/2 ở từng nhóm quần thể, chủng tộc 
khác nhau. Điều này cũng giải thích thêm sự khác biệt có ý nghĩa về tỷ lệ đột 
biến gen COL1A1/2 giữa Việt Nam và các nước khác trên thế giới.  
Trong 34 biến thể đột biến gen COL1A1 và 22 biến thể đột biến gen 
COL1A2, chúng tôi phát hiện 17 biến thể đột biến mới của COL1A1 và 10 của 
COL1A2 chưa được các nghiên cứu trước đây đề cập đến. Nghiên cứu đã phát 
hiện nhiều biến thể đột biến mới hơn các nghiên cứu của Stephen (2014), Lin 
(2015), Yang (2011) và Ward (2001). Liên quan đến sự thay thế của acide amin 
trong đột biến COL1A1 và COL1A2, glycine được thay thế nhiều nhất chiếm tỷ 
lệ 64.3%. Các kết quả nghiên cứu này khẳng định sự cần thiết phải tiếp tục 
nghiên cứu để phát hiện đột biến gen không phải collagen týp I trên quần thể 
người Việt Nam.  
 
Kết luận 
1.  Kết quả nghiên cứu cho thấy tồn tại nhiều thách thức trong bệnh TXBT tại 
Việt Nam. Tỷ lệ bệnh nhân chưa được phát hiện cao, đặc biệt ở các gia đình 
không có tiền sử, hoặc bệnh nhân ở thể nhẹ. Các đặc điểm về lâm sàng và 
thể loại ở Việt Nam cũng giống các nước khác trên thế giới. Tuy nhiên tỷ lệ 
biến chứng như gãy xương và biến chứng khác gặp cao hơn so với các 
nghiên cứu đã công bố. Nghiên cứu bệnh TXBT tại Việt Nam này có thể 
dùng để hướng dẫn các nhân viên y tế phát hiện, chẩn đoán bệnh nhân 
TXBT qua các dấu hiệu lâm sàng, giúp chẩn đoán sớm và ngăn ngừa các 
biến chứng cho bệnh nhân. Cần thực thi các điều tra và thực hiện các dịch vụ 
y tế rộng rãi, để giúp bệnh nhân TXBT cải thiện được chất lượng cuộc sống 
của họ và gia đình. 
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2.  Tạo răng bất toàn gặp ở 60.96% trường hợp bệnh nhân TXBT. Phân tích gen 
cho thấy có sự liên quan giữa tạo răng bất toàn và bất bình thường của 
collagen týp I. Các triệu chứng liên quan đến khớp cắn như độ cắn chìa, độ 
cắn phủ, độ cắn hở, cắn chìa răng dưới, cắn chéo răng sau và mất răng là rất 
phổ biến. Do những triệu chứng này có tác động nhiều đến cuộc sống của 
bệnh nhân, nên cần phải theo dõi và điều trị về chỉnh nha giúp cho bệnh 
nhân cải thiện được chất lượng cuộc sống. 
3.  Phân tích đột biến gen cho thấy tỷ lệ đột biến collagen týp I thấp hơn so với 
các quần thể khác trên thế giới. Nghiên cứu của chúng tôi phát hiện tỷ lệ đột 
biến của gen COL1A1 và A2 là 59.4%, trong khi các báo cáo của các nghiên 
cứu khác có thể đến 90%. Điều đó thể hiện kiểu gen đột biến ở người Việt 
Nam liên quan đến đột biến lặn các gen không thuộc collagen týp I. Cần tiếp 
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